var title_f27_52_28480="Peace sign to assess ulnar nerve motor function";
var content_f27_52_28480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Peace sign to assess ulnar nerve motor function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Injury to the ulnar nerve impairs function of the dorsal and palmar interossei making patients unable to abduct and adduct their fingers. This can be tested by having the patient make a peace sign, as shown in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28480=[""].join("\n");
var outline_f27_52_28480=null;
var title_f27_52_28481="Hirschsprung dz barium enema";
var content_f27_52_28481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59877%7EPEDS%2F58657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59877%7EPEDS%2F58657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hirschsprung's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema of an infant with Hirschsprung's disease showing the transition zone between the lower aganglionic bowel and the normal colon above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George D Ferry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional constipation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This unprepped barium enema is compatible with functional constipation. The rectum is mildly dilated with stool and there is no evidence of obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George D Ferry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28481=[""].join("\n");
var outline_f27_52_28481=null;
var title_f27_52_28482="Ureteric bud";
var content_f27_52_28482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ureteric bud",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation of the hindgut and cloaca at the end of the fifth week. The ureteric bud penetrates the metanephric mesoderm (blastema).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28482=[""].join("\n");
var outline_f27_52_28482=null;
var title_f27_52_28483="Thumb spica cast 7";
var content_f27_52_28483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Before applying the final layer of casting material, fold back the ends of the stockinette. The cast underlayment should roll over the edge of the cast material providing cushioning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28483=[""].join("\n");
var outline_f27_52_28483=null;
var title_f27_52_28484="Pilocarpine (systemic): Patient drug information";
var content_f27_52_28484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pilocarpine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=see_link\">",
"     see \"Pilocarpine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7876?source=see_link\">",
"     see \"Pilocarpine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pilocarpine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Passing urine often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12290 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28484=[""].join("\n");
var outline_f27_52_28484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505050\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505051\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024531\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024530\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024535\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024536\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024538\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024533\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024534\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024539\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024540\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=related_link\">",
"      Pilocarpine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28485="Sesamoid fractures of the foot";
var content_f27_52_28485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sesamoid fractures of the foot",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Jocelyn R Gravlee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Robert L Hatch, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28485/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/52/28485/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sesamoid bones are found embedded in the tendons near many joints. They function to protect the tendon and enhance its mechanical effect. Most sesamoid bones are small and resemble grains of sesame; the meaning of the word's greek root is \"shaped like a sesame.\" The two largest sesamoids in the foot reside near the first metatarsophalangeal (MTP) joint and are susceptible to fracture.",
"   </p>",
"   <p>",
"    This topic review will discuss sesamoid fractures of the foot in adults. Other foot fractures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"     \"Toe fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=see_link\">",
"     \"Stress fractures of the metatarsal shaft\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=see_link\">",
"     \"Metatarsal shaft fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two relatively large sesamoids adjacent to the first metatarsophalangeal (MTP) joint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80813 \" href=\"UTD.htm?15/6/15471\">",
"     image 1",
"    </a>",
"    ). Injuries to these sesamoids comprise 12 percent of injuries to the great toe complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/1\">",
"     1",
"    </a>",
"    ]. Small sesamoids are occasionally seen elsewhere in the foot, most notably beneath the fifth MTP joint (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53384 graphicRef74938 graphicRef66231 \" href=\"UTD.htm?24/21/24917\">",
"     image 2A-C",
"    </a>",
"    ). These smaller sesamoids are rarely of clinical significance (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The sesamoids of the first MTP joint are embedded within the tendon of the flexor hallucis brevis and allow for increased dorsiflexion of the MTP. They are also involved in shock absorption, reduction of friction, and protection of tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/2\">",
"     2",
"    </a>",
"    ]. The medial (ie, tibial) sesamoid is thought to bear greater force during the normal gait cycle and is more commonly fractured from either direct force or cumulative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The lateral (ie, fibular) sesamoid is injured much less often.",
"   </p>",
"   <p>",
"    It is important to recognize that sesamoids are sometimes \"partite,\" ie, one sesamoid is made up of two or three separate pieces (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62386 \" href=\"UTD.htm?4/36/4673\">",
"     image 3",
"    </a>",
"    ). A study of 35 cadaveric feet found the incidence of partite sesamoids to be 11.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/5\">",
"     5",
"    </a>",
"    ]. This finding is comparable to other studies. Partite sesamoids are frequently bilateral. Hence, bilateral comparison views are sometimes helpful in distinguishing a partite from a fractured sesamoid. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Partite sesamoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct blows and forced hyperdorsiflexion can lead to acute sesamoid fractures. However, stress fractures are more common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .) One study found sesamoid injuries occur most commonly in long distance running and in sports that require rapid acceleration and deceleration, such as tennis, racquetball, football, soccer, and volleyball [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a sesamoid stress fracture usually complain of poorly localized pain around the first metatarsophalangeal (MTP) joint for several weeks. Swelling is not generally seen until the injury has progressed. Erythema is typically absent.",
"   </p>",
"   <p>",
"    Often, the patient is unable to localize the pain until the examiner directly palpates the injured sesamoid. Passive dorsiflexion of the first MTP joint can elicit pain in sesamoid fractures. If this movement does not produce pain and a fracture is suspected, some suggest holding the MTP in maximal dorsiflexion and deeply palpating the suspected area, while the patient tries to plantar flex the great toe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of sesamoid fractures includes: bursitis, sesamoiditis, osteochondritis, chondromalacia, tenosynovitis, flexor hallucis brevis tendonitis, medial plantar digital nerve impingement, and sesamoid-metatarsal arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/7\">",
"     7",
"    </a>",
"    ]. History and examination alone are insufficient to distinguish these injuries from a stress fracture of the sesamoid; radiographic studies are required.",
"   </p>",
"   <p>",
"    A presumptive diagnosis of sesamoiditis is made if the following conditions are met [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal pain is present over a sesamoid.",
"     </li>",
"     <li>",
"      Pain with passive dorsiflexion of the MTP is present.",
"     </li>",
"     <li>",
"      No swelling or redness is present.",
"     </li>",
"     <li>",
"      Radiographs show no fracture is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, if rest from activity and shoe orthoses do not resolve pain in two to four weeks, other diagnoses, such as a subtle sesamoid fracture, should be entertained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Approach to imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard anteroposterior (AP), oblique, and lateral views of the foot are generally sufficient to demonstrate sesamoid fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74397 graphicRef52221 \" href=\"UTD.htm?15/59/16309\">",
"     image 4A-B",
"    </a>",
"    ). Dedicated sesamoid views, such as lateral oblique (which shows the fibular sesamoid), medial oblique (which shows the tibial sesamoid), and axial (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76929 \" href=\"UTD.htm?5/10/5280\">",
"     image 5",
"    </a>",
"    ) views can be obtained, if standard x-rays are negative but there remains a high index of suspicion.",
"   </p>",
"   <p>",
"    Fractures of the sesamoids are usually transverse (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74397 graphicRef52221 \" href=\"UTD.htm?15/59/16309\">",
"     image 4A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/8\">",
"     8",
"    </a>",
"    ]. Like scaphoid fractures, sesamoid fractures may not be apparent on initial radiographs. X-rays should be repeated after two weeks of presumptive therapy if a fracture is strongly suspected but initial films are negative. Rarely, magnetic resonance imaging (MRI) may be needed for a definitive diagnosis if it remains unclear. Bone marrow edema may suggest a stress fracture, but sesamoiditis may show similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Partite sesamoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partite sesamoids, a normal variant, may be confused with fractured sesamoids. Fracture lines of sesamoids usually have irregular edges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74397 graphicRef52221 \" href=\"UTD.htm?15/59/16309\">",
"     image 4A-B",
"    </a>",
"    ), in contrast to the smooth borders of a partite sesamoid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62386 \" href=\"UTD.htm?4/36/4673\">",
"     image 3",
"    </a>",
"    ). In addition, partite sesamoids usually demonstrate even cortication around their entire circumference (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51617 \" href=\"UTD.htm?31/46/32480\">",
"     image 6",
"    </a>",
"    ), whereas the fracture line of a sesamoid will lack cortication (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74397 graphicRef52221 \" href=\"UTD.htm?15/59/16309\">",
"     image 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bilateral comparison plain radiographs, a bone scan, or MRI can be obtained to distinguish a partite sesamoid from a fracture when plain films are unclear. Fracture is unlikely if tenderness is minimal and comparison radiographs demonstrate a partite sesamoid with similar appearance. One should bear in mind, however, that partite sesamoids can sustain fractures. Such fractures generally demonstrate modest point tenderness until healing is underway.",
"   </p>",
"   <p>",
"    A bone scan may also help differentiate a partite sesamoid from a fracture. However, it is a non-specific study: sesamoiditis can result in a positive bone scan showing diffuse uptake in the plantar area of the first metatarsophalangeal (MTP) joint [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians commonly mistake sesamoids and accessory bones for avulsion fractures on x-rays. To avoid this error, it is helpful to know the location of the most common sesamoids and accessory bones. In the foot, the most common sesamoids lie in the area of the first and fifth MTP joints. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Relevant anatomy'",
"    </a>",
"    above.) The most common accessory bones are found proximal to the base of the fifth (ie, small) metatarsal (os vesalianum), adjacent to the cuboid in the peroneus longus tendon (os peroneum), adjacent to the navicular (os tibiale externum), and posterior to the talus (os trigonum) (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ). A detailed discussion of accessory bones is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures require urgent referral. Displaced sesamoid fractures, which are rare, should also be referred. Early referral should also be considered for athletes, dancers, and other patients who are anxious to return to full activity.",
"   </p>",
"   <p>",
"    For nondisplaced fractures, referral is advised if healing has not occurred by four to six months (nonunion) or if symptoms are still bothersome after four to six months. Patients requiring referral can be sent to either a podiatrist or an orthopedist, depending on local availability and expertise. Podiatrists often have more experience in both conservative and operative care of sesamoid injuries, with the exception of orthopedists who specialize in the foot and ankle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can treat sesamoid fractures in several ways. Abstaining from the activity thought to have caused the fracture is common to all approaches. In addition, some type of padding or bracing footwear is used, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C or O-shaped padding around the sesamoid to unload it",
"     </li>",
"     <li>",
"      Molded orthosis",
"     </li>",
"     <li>",
"      Wood-soled shoe",
"     </li>",
"     <li>",
"      Short-leg cast",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of symptoms often dictates which approach is chosen. If the patient is pain-free with weight-bearing, some treat with a molded orthosis for six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/7\">",
"     7",
"    </a>",
"    ]. With acute traumatic fractures or highly symptomatic stress fractures, some recommend casting for three to four weeks followed by a firm-soled shoe and padding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/5\">",
"     5",
"    </a>",
"    ]. Others recommend no weight-bearing during the initial three to four weeks, but this level of protection is unnecessary in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment remains controversial. Some authors claim prolonged conservative treatment with immobilization is ineffective in treating sesamoid fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. Nonetheless, before pursuing surgery, conservative treatment using one of the approaches described above seems prudent. We recommend using the least intrusive and least expensive intervention that achieves satisfactory pain control during ambulation. Often, treatment with C or O pads and a stiff-soled shoe yields satisfactory results.",
"   </p>",
"   <p>",
"    Nonopioid analgesics may be used to help control pain. While some authors recommend nonsteroidal antiinflammatory drugs (NSAIDs) to treat pain from stress fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/11\">",
"     11",
"    </a>",
"    ], others have questioned their use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/12\">",
"     12",
"    </a>",
"    ]. The effects of NSAIDs upon fracture healing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H22#H22\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Healing of musculoskeletal injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant pain during ambulation can be reduced by maximizing the use of physical interventions such as orthoses. Pain during rest can be reduced using medications other than NSAIDS, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Padding, use of a firm-soled shoe, or immobilization should be continued for six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/4\">",
"     4",
"    </a>",
"    ]. Follow-up is performed one to two weeks after diagnosis and monthly thereafter. It is not uncommon for sesamoid fractures to remain painful for several months.",
"   </p>",
"   <p>",
"    If pain persists and the fracture does not heal, the goal of treatment changes from bone healing to pain reduction. This can involve partial excision of the sesamoid. It is unclear when this change in treatment priorities should be made. Some diagnose permanent nonunion of the sesamoid bone if no healing has occurred six months after the fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/6\">",
"     6",
"    </a>",
"    ]. Referral is therefore recommended if significant symptoms remain four to six months after diagnosis.",
"   </p>",
"   <p>",
"    Surgical options include partial sesamoidectomy, bone grafting, or complete sesamoidectomy in cases involving avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/6\">",
"     6",
"    </a>",
"    ]. Total excision of both sesamoids is not recommended, as this can lead to disabling deformity (the so-called \"cock-up toe\") [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28485/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RETURN TO WORK AND SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial six to eight week treatment period, patients may return to activities as their symptoms permit. Mild persistent pain can be treated with a pad to unload the sesamoid. Patients should be told to increase their activities by",
"    <strong>",
"     no more than 10 percent per week",
"    </strong>",
"    . Rapid increases in the volume or intensity of activity can lead to recurrence of stress fractures. The patient should cut back on activities immediately if symptoms increase and seek reevaluation if they persist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sesamoid fractures are a common cause of pain near the first metatarsophalangeal (MTP) joint. The majority of these fractures are stress fractures that can be managed nonsurgically.",
"     </li>",
"     <li>",
"      The two relatively large sesamoids adjacent to the first MTP joint are the most frequently injured sesamoids. Of these, the medial (tibial) sesamoid is thought to bear more force during gait and is more commonly fractured. Sesamoids are sometimes \"partite\" (one sesamoid comprised of two or three separate pieces). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Relevant anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stress fractures are the most common type of sesamoid fracture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a sesamoid fracture usually complain of poorly localized pain around the first MTP joint for several weeks. Swelling is not generally seen until the injury has progressed. Erythema is typically absent. Direct palpation of the sesamoid and passive dorsiflexion of the first MTP joint can elicit and localize pain in sesamoid fractures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard anteroposterior (AP), oblique, and lateral views of the foot are generally sufficient to demonstrate sesamoid fractures. Sesamoid fractures may not appear on initial x-rays. Sesamoid fractures are generally transverse. Lack of cortication and irregular borders help distinguish fracture lines from partite sesamoids. Sesamoid and accessory bones are commonly mistaken for avulsion fractures. Special views, bilateral comparison views, bone scan, or MRI can be helpful when the diagnosis remains unclear. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open fractures (generally following significant trauma) require urgent referral. Displaced sesamoid fractures, which are rare, should also be referred. For nondisplaced fractures, referral is advised if healing has not occurred by four to six months (nonunion), or if symptoms remain bothersome after four to six months. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is controversial. Abstaining from the activity thought to have caused the fracture is common to all approaches. In addition, some type of padding or bracing footwear is used, including: C or O-shaped padding around the sesamoid to unload it; a molded orthosis; a wooden-soled shoe; or a short leg cast. The severity of symptoms often dictates which approach is chosen. Nonopioid analgesics may be used. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Padding, use of a firm-soled shoe, or immobilization should be continued for six to eight weeks. Initial follow-up is performed one to two weeks after diagnosis and monthly thereafter. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial six to eight-week treatment period, patients may return to activities as their symptoms permit. Patients should be told to increase their activities by",
"      <strong>",
"       no more than 10 percent per week",
"      </strong>",
"      . Rapid increases in the volume or intensity of activity can lead to recurrence. Prolonged symptoms are not uncommon and may necessitate referral for possible surgery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Return to work and sports'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/1\">",
"      McBryde AM Jr, Anderson RB. Sesamoid foot problems in the athlete. Clin Sports Med 1988; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/2\">",
"      Richardson EG. Injuries to the hallucal sesamoids in the athlete. Foot Ankle 1987; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/3\">",
"      Jahss MH. The sesamoids of the hallux. Clin Orthop Relat Res 1981; :88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/4\">",
"      Hockenbury RT. Forefoot problems in athletes. Med Sci Sports Exerc 1999; 31:S448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/5\">",
"      Scranton PE Jr, Rutkowski R. Anatomic variations in the first ray: Part II. Disorders of the sesamoids. Clin Orthop Relat Res 1980; :256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/6\">",
"      Weiss JS. Fracture of the medial sesamoid bone of the great toe: controversies in therapy. Orthopedics 1991; 14:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/7\">",
"      Mittlmeier T, Haar P. Sesamoid and toe fractures. Injury 2004; 35 Suppl 2:SB87.",
"     </a>",
"    </li>",
"    <li>",
"     Eiff, MP, Hatch, RL, Calmbach, WL. Fracture Management for Primary Care, 2nd ed, Saunders, Philadelphia, PA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/9\">",
"      Wall J, Feller JF. Imaging of stress fractures in runners. Clin Sports Med 2006; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/10\">",
"      Van Hal ME, Keene JS, Lange TA, Clancy WG Jr. Stress fractures of the great toe sesamoids. Am J Sports Med 1982; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/11\">",
"      Sanderlin BW, Raspa RF. Common stress fractures. Am Fam Physician 2003; 68:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28485/abstract/12\">",
"      Stovitz SD, Arendt EA. NSAIDs should not be used in treatment of stress fractures. Am Fam Physician 2004; 70:1452, 1454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 224 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28485=[""].join("\n");
var outline_f27_52_28485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Approach to imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Partite sesamoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RETURN TO WORK AND SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/224|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/6/15471\" title=\"diagnostic image 1\">",
"      1st mcp sesamoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/1/14367\" title=\"diagnostic image 2A\">",
"      Sesamoid under 5th mcp AP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/50/15151\" title=\"diagnostic image 2B\">",
"      Sesamoid under 5th mcp oblique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/3/55\" title=\"diagnostic image 2C\">",
"      Sesamoid under 5th mcp lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/36/4673\" title=\"diagnostic image 3\">",
"      Bipartite medial sesamoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/48/38657\" title=\"diagnostic image 4A\">",
"      Trans fx medial sesamoid A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/26/14767\" title=\"diagnostic image 4B\">",
"      Trans fx medial sesamoid B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/10/5280\" title=\"diagnostic image 5\">",
"      Axial view sesamoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/46/32480\" title=\"diagnostic image 6\">",
"      Bipartite lateral sesamoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/224|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/7/30835\" title=\"figure 1A\">",
"      Foot anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38530\" title=\"figure 1B\">",
"      Foot anatomy medial view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/20/2375\" title=\"figure 1C\">",
"      Foot anatomy superior view",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=related_link\">",
"      Metatarsal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=related_link\">",
"      Stress fractures of the metatarsal shaft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=related_link\">",
"      Toe fractures in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28486="CLL lymph node";
var content_f27_52_28486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Lymph node biopsy from a patient with chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node biopsy from a patient with chronic lymphocytic leukemia. At low magnification (A), there is a vaguely nodular (pseudofollicular) pattern. Higher magnification (B) shows a predominance of small lymphocytes with scattered larger cells known as prolymphocytes and paraimmunoblasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28486=[""].join("\n");
var outline_f27_52_28486=null;
var title_f27_52_28487="Renal ectopic and fusion anomalies";
var content_f27_52_28487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal ectopic and fusion anomalies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Aoife M Waters, MD, PhD FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Norman D Rosenblum, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28487/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/52/28487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ectopy and fusion are common congenital anomalies of the kidney and urinary tract (CAKUT), and result from disruption of the normal embryologic migration of the kidneys. Although children with these anomalies are generally asymptomatic, some children develop symptoms due to complications, such as infection, renal calculi, and urinary obstruction.",
"   </p>",
"   <p>",
"    Ectopic and fusion anomalies of the kidney with their associated complications will be reviewed here. An overview and the evaluation of congenital anomalies of the kidney and urinary tract, including radiological investigations, are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL EMBRYOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal embryologic development of the kidney occurs in three stages; pronephros, mesonephros, and metanephros. The last stage, the metanephros forms the permanent kidney and is first detected at five to six weeks of gestation (",
"    <a class=\"graphic graphic_figure graphicRef68500 \" href=\"UTD.htm?12/41/12948\">",
"     figure 1",
"    </a>",
"    ). The metanephros is composed of the metanephric mesenchyme and ureteral bud (caudal portion of the mesonephric duct).",
"   </p>",
"   <p>",
"    The metanephros is initially positioned in the pelvis opposite the sacral somites. Rapid caudal growth results in the migration of the developing kidney from the pelvis to the retroperitoneal renal fossa, which lies on either side of the spine opposite the second lumbar vertebra. As each kidney ascends, it rotates through 90 degrees such that the renal hilum is directed medially as the kidney reaches its final position. Migration and rotation are completed by the eighth week of gestation.",
"   </p>",
"   <p>",
"    The ascending kidney derives its vascular supply locally from neighboring vessels. As the kidneys reach their permanent position, renal arteries and veins develop and provide vascular support. As a result, ectopic kidneys usually contain numerous small vessels and reflect the continuous changes in blood supply of the developing kidneys during the course of renal ascent.",
"   </p>",
"   <p>",
"    Positional (ectopy) and fusion anomalies occur when this normal embryogenic migration is disrupted and are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RENAL ECTOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ectopy occurs when the kidney does not normally ascend to the retroperitoneal renal fossa (level of the second lumbar vertebra). Simple congenital ectopy refers to a kidney that lies on the correct side of the body but lies in an abnormal position. Kidneys that cross the midline are referred to as crossed renal ectopy. Crossed renal ectopy can occur with and without fusion to the contralateral kidney (",
"    <a class=\"graphic graphic_figure graphicRef60213 \" href=\"UTD.htm?12/30/12771\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Crossed fused ectopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ectopic kidneys that do not ascend above the pelvic brim are commonly called pelvic kidneys. Rarely, the ectopic kidney is found in the thorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bilateral renal ectopy has also been reported but is a rare occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ectopic kidney fails to rotate normally resulting in a shift of the renal axis so that the renal pelvis is directed anteriorly rather than medially. The blood supply of the ectopic kidney is variable and may come from the iliac arteries, aorta, and at times, the hypogastric and middle sacral arteries.",
"   </p>",
"   <p>",
"    The incidence of renal ectopy is reported as 1 in 1000 autopsies. A similar rate was reported in a study of 13,705 fetuses with antenatal ultrasounds performed in a tertiary center in Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/4\">",
"     4",
"    </a>",
"    ]. However, a study that screened 132,686 Taiwanese schoolchildren (6 to 15 years of age) found a lower incidence of 1 in 5000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/5\">",
"     5",
"    </a>",
"    ]. In this study, 30 cases of ectopic kidneys were detected by a \"quick\" screening renal ultrasound in 20 boys and 10 girls. Further imaging located the ectopic kidney in the lower lumbar region of 21 children, and in the pelvis and the thorax of five and two other children, respectively. The kidney crossed the midline in a further two children. This study may have underestimated the incidence of renal ectopy because of limitations of the screening technique used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical findings of renal ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with renal ectopy are asymptomatic. The diagnosis is often made coincidentally during routine antenatal or postnatal ultrasonography. This was illustrated in a case series of 99 children with renal ectopy, of which 79 were asymptomatic at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/6\">",
"     6",
"    </a>",
"    ]. The diagnosis was made by either antenatal or postnatal ultrasonography.",
"   </p>",
"   <p>",
"    In a fetus with normal amniotic fluid volume, the most likely cause of an absent kidney in the renal fossa is an ectopic kidney as demonstrated in the previously mentioned retrospective review of 13,705 fetuses who had antenatal ultrasounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/4\">",
"     4",
"    </a>",
"    ]. Of 40 cases with an empty renal fossa identified, the underlying cause in 24 patients was renal ectopia, and unilateral renal agenesis and horseshoe kidney in 13 and 2, respectively. Crossed fused renal ectopy was detected in one patient. Thus, a finding of an empty renal fossa should direct the ultrasonographer to search for an ectopic kidney.",
"   </p>",
"   <p>",
"    In patients diagnosed symptomatically, findings at presentation are generally related to associated complications, such as urinary tract infection, obstruction, and renal calculi. Symptoms include abdominal pain, fever, hematuria, or incontinence from an ectopic ureter. On examination, an abdominal mass may be palpable or hypertension detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"     \"Ectopic ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the previously mentioned case series of 99 patients, at presentation, 12 of the 20 patients with symptomatic renal ectopy had signs of urinary tract infection, four had abdominal pain, two had a palpable abdominal mass, one had hematuria and one was incontinent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ectopic kidney generally has decreased function. As illustrated in the case series of 99 patients, decreased renal function was detected by 9mTc-dimercaptosuccinic acid (DMSA) renal scan in 74 of 82 cases of simple unilateral renal ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely in female patients, persistent urinary incontinence characterized by continuous dampness of their underwear can be secondary to a small ectopic pelvic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Renal sonogram may not be sensitive enough to identify the tiny ectopic kidney, which may be associated with compensatory hypertrophy of the normal contralateral kidney. A high clinical suspicion should initiate evaluation with a DMSA scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging urogram to look for a dilated ureter and associated ectopic renal nubbin. Laparoscopic removal will resolve the incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Other anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high incidence of other urological abnormalities has been associated with renal ectopy. Vesicoureteral reflux (VUR) is the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. The following urological abnormalities were noted in the case series of 99 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VUR occurred in 20 percent of crossed renal ectopy, 30 percent of simple renal ectopy, and 70 percent in bilateral simple renal ectopy.",
"     </li>",
"     <li>",
"      Other genitourinary abnormalities included:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Contralateral renal dysplasia in four cases; three with multicystic dysplasia and one with renal agenesis",
"     </li>",
"     <li>",
"      Cryptorchidism in five cases",
"     </li>",
"     <li>",
"      Hypospadias in five cases",
"     </li>",
"     <li>",
"      Hydronephrosis in three ectopic and eight contralateral kidneys; in one ectopic kidney, ureteropelvic obstruction was detected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In girls, genital anomalies such as agenesis of the uterus and vagina (eg, m&uuml;llerian agenesis and Mayer-Rokitansky-K&uuml;ster-Hauser Syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/10\">",
"     10",
"    </a>",
"    ] or unicornuate uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/11\">",
"     11",
"    </a>",
"    ] have been associated with ectopic kidneys. In girls with uterovaginal atresia, there is often only a single ectopic kidney. In these patients as well as those with contralateral renal dysplasia, renal function is impaired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ectopic kidney can be associated with other nonrenal anomalies (adrenal, cardiac, and skeletal abnormalities) and as a clinical feature in syndromes such as CHARGE syndrome (coloboma, heart disease, atresia choanae, retarded growth and development, genital hypoplasia and ear anomalies) and VACTERL syndrome (vertebral, anal, cardiac, tracheal, esophageal, renal, limb anomalies) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Thoracic kidneys are often associated with congenital diaphragmatic hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation of renal ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an ectopic kidney is detected, evaluation should include a careful physical examination for other anomalies.",
"   </p>",
"   <p>",
"    Radiological testing is recommended to detect other urological abnormalities that impact on renal function. Detailed descriptions of these studies including voiding cystourethrogram (VCUG), dynamic (eg, such as technetium 99m-mercaptotriglycylglycine [Tc99mMAG3] and 99mTc-diethylenetriamine pentaacetic acid [DTPA]) and static renal scans are found separately.",
"   </p>",
"   <p>",
"    Postnatal renal ultrasonography confirms the antenatal diagnosis of renal ectopy and defines the underlying anatomy, including the presence of hydronephrosis.",
"   </p>",
"   <p>",
"    Voiding cystourethrogram (VCUG) should be performed in patients with horseshoe kidney with a history of urinary tract infection because of the increased association with vesicoureteral reflux (VUR). If VUR is detected, then prophylactic antibiotics should be considered, especially in patients who have a history of recurrent urinary tract infections.",
"   </p>",
"   <p>",
"    A serum creatinine should be obtained to assess renal function in children with bilateral renal disease or progressive hydronephrosis.",
"   </p>",
"   <p>",
"    In our practice, further evaluation is based upon the results of these three studies (postnatal ultrasound, VCUG, and serum creatinine) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with a normal-appearing contralateral kidney and no evidence of hydronephrosis in the ectopic kidney, no further evaluation is required.",
"     </li>",
"     <li>",
"      If the serum creatinine is elevated or if the contralateral kidney appears abnormal, a 99mTc-DMSA renal scan should be performed to assess the differential renal function of both kidneys. In patients with decreased renal function, urologic or nephrologic consultation should be sought.",
"     </li>",
"     <li>",
"      If there is severe hydronephrosis and the VCUG examination is normal, then a diuretic renogram with (99mTc)-mercaptotriglycylglycine (MAG-3) or technetium 99mTc-diethylenetriamine pentaacetic acid (DTPA) should be performed to detect obstruction.",
"     </li>",
"     <li>",
"      If the hydronephrosis is mild or moderate and the VCUG examination is normal, then follow-up ultrasonography should be performed three to six months later. If there is progressive hydronephrosis, then a MAG-3 or DTPA diuretic renogram should be performed to detect obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more complete description of the radiological studies discussed before is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of other anomalies, the prognosis for a patient with an ectopic kidney is excellent. This was illustrated in a retrospective study from a single Dutch center of 41 patients; 26 had simple ectopy (ie, unilateral pelvic kidney) and 15 had crossed renal ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/14\">",
"     14",
"    </a>",
"    ]. The median age at diagnosis was 0.2 years. In three patients, a defined syndrome was diagnosed (ie, Treacher Collins, Mayer-Rokitansky-Kuster and Goldenhar syndromes). At follow-up (median age of 7.7 years), blood pressure, glomerular filtration rate, and albuminuria were stable without evidence of deterioration. There was no difference in outcome between patients with simple ectopy versus those with crossed ectopia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RENAL FUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal fusion occurs when a portion of one kidney is fused to the other. The most common fusion anomaly is the horseshoe kidney, which involves abnormal migration of both kidneys (ectopy), resulting in fusion. This differs from crossed fused renal ectopy, which usually involves abnormal movement of only one kidney across the midline with fusion of the contralateral noncrossing kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Horseshoe kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common fusion anomaly is the horseshoe kidney, which occurs with fusion of one pole of each kidney (",
"    <a class=\"graphic graphic_figure graphicRef75867 \" href=\"UTD.htm?38/13/39120\">",
"     figure 3",
"    </a>",
"    ). The reported incidence based upon data from birth defect registries varies from 0.4 to 1.6 to 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/15\">",
"     15",
"    </a>",
"    ]. A higher incidence (1 in 600 births) was reported from a single center that reviewed the results of abdominal computerized tomography, renal ultrasonography and excretory urography of all infants younger than 6 months of age over a six-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this higher incidence is most likely an overestimation, as this was a highly selected group of patients who underwent radiologic evaluation who could have a higher incidence of horseshoe kidney compared to the general population.",
"   </p>",
"   <p>",
"    In more than 90 percent of cases, fusion occurs at the lower poles; as a result two separate excretory renal units and ureters are maintained. The isthmus (fused portion) may lie over the midline (symmetric horseshoe kidney) or lateral to the midline (asymmetric horseshoe kidney). Depending on the degree of fusion, the isthmus can be composed of renal parenchyma or a fibrous band (",
"    <a class=\"graphic graphic_figure graphicRef75867 \" href=\"UTD.htm?38/13/39120\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fusion is thought to occur before the kidneys ascend from the pelvis to their normal dorsolumbar position. This is usually between the fifth to ninth week of gestation. The majority of horseshoe kidneys with a parenchymal isthmus result from an abnormal migration of the posterior nephrogenic area, which generally occurs before the fifth week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Horseshoe kidneys with a fibrous isthmus arise from fusion after the fifth week of gestation, before renal ascent. If large portions of the renal parenchyma fuse, the fusion anomaly loses its horseshoe appearance and appears as a flattened disc or lump kidney.",
"   </p>",
"   <p>",
"    Early fusion also causes abnormal rotation of the developing kidneys. As a result, the axis of each kidney is shifted so that the renal pelvis lies anteriorly and the ureters either traverse over the isthmus of the horseshoe kidney or the anterior surface of the fused kidney (",
"    <a class=\"graphic graphic_figure graphicRef75867 \" href=\"UTD.htm?38/13/39120\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fusion anomalies seldom ascend to the dorsolumbar position of normal kidneys and are typically found in the pelvis or at the lower lumbar vertebral level (L4 or L5). The blood supply of the fused kidney is variable and may come from the iliac arteries, aorta, and at times, the hypogastric and middle sacral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with horseshoe kidneys are asymptomatic. In these patients, the horseshoe kidney is diagnosed by coincidence (eg, routine antenatal ultrasonography). However, some patients present with pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria due to obstruction or infection.",
"   </p>",
"   <p>",
"    Hydronephrosis is reported to occur in approximately 80 percent of children with horseshoe kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Causes of hydronephrosis include vesicoureteral reflux (VUR) or obstruction of the collecting system by external ureteric compression by an aberrant vessel, renal calculi, or from ureteropelvic junction (UPJ) obstruction. UPJ obstruction is associated with the high insertion of the ureters into the renal pelvis and displacement of the fused isthmus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal calculi are reported to occur in 20 percent of cases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73581 \" href=\"UTD.htm?22/54/23393\">",
"     image 1",
"    </a>",
"    ). Obstruction resulting in urinary stasis and increased risk of infection have been thought to be the major contributing factors for stone formation. However, a retrospective review reported a high rate of metabolic abnormalities (including hypercalciuria, hyperoxaluria, hyperuricosuria, and hypocitraturia) in patients with horseshoe kidney and renal calculi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, others have found no difference in the frequency of metabolic abnormalities associated with renal calculi between patients with a horseshoe kidney and the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a horseshoe kidney are at increased risk for infection because of the increased likelihood of urinary stasis. Impaired urinary drainage resulting in stasis is thought to be due to the high insertion of the renal ureter (which leads to UPJ obstruction).",
"   </p>",
"   <p>",
"    One-third to one-half of patients with horseshoe kidneys will have another congenital anomaly, particularly another urological abnormality (VUR) or a genital anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urological anomalies &ndash; VUR and UPJ obstruction are common findings in patients with horseshoe kidneys. As an example, in a case series of 52 patients, VUR and UPJ obstruction were noted in 13 and 12 patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/25\">",
"       25",
"      </a>",
"      ]. Other urological abnormalities reported in children with horseshoe kidneys include ureteral duplication, ectopic ureter, ureterocele, and a retrocaval ureter [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Anomalies of the collecting system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genital anomalies &ndash; Genital anomalies associated with a horseshoe kidney include bicornuate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      septate uterus in girls, and hypospadias and undescended testis in boys. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"       \"Hypospadias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Syndromes &ndash; Horseshoe kidney can be a feature of many syndromes including genetic disorders such as Turner syndrome, Trisomy 13, 18, and 21 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H8#H8\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Numeric abnormalities'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a horseshoe kidney appear to have an increased risk for Wilms tumor. This was illustrated in a retrospective review of 8617 patients from the National Wilms Tumor Study between 1969 and 1998 that identified 41 patients with Wilms tumor in a horseshoe kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=see_link\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Evaluation of renal fusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a horseshoe kidney is detected, evaluation is dependent upon the clinical concern of whether obstructive uropathy is present.",
"   </p>",
"   <p>",
"    If the horseshoe kidney is detected antenatally, a postnatal ultrasound should be performed to confirm the diagnosis and define the underlying anatomy including whether hydronephrosis is present.",
"   </p>",
"   <p>",
"    If there is a history of urinary tract infection, the evaluation should include a VCUG to determine whether VUR is present because VUR is a common finding in patients with a horseshoe kidney.",
"   </p>",
"   <p>",
"    A serum creatinine should be performed to assess renal function if there is evidence of obstruction.",
"   </p>",
"   <p>",
"    In our practice, further evaluation is based upon the results of these three studies (postnatal ultrasound, VCUG, and serum creatinine) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with normal serum creatinine for age and no evidence of hydronephrosis, no further evaluation is required.",
"     </li>",
"     <li>",
"      If the serum creatinine is elevated, additional evaluation of renal function by DMSA renal radionuclide scan should be performed to assess differential renal function and evidence of renal scarring.",
"     </li>",
"     <li>",
"      Patients with hydronephrosis not due to VUR should be evaluated by a diuretic radionuclide scan with either (99mTc)-mercaptotriglycylglycine (MAG-3) or technetium 99mTc-diethylenetriamine pentaacetic acid (DTPA) to differentiate hydronephrosis due to obstruction from nonobstructive urinary stasis or pelvic dilatation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/28\">",
"       28",
"      </a>",
"      ]. If obstruction is present, then an urological consultation should be sought. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=see_link\">",
"       \"Postnatal management of antenatal hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of cases, patients have an excellent prognosis without any therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with VUR, prophylactic antibiotic therapy to prevent urinary tract infection should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=see_link\">",
"     \"Management of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with obstruction of the collecting system should be referred to urologist with expertise in treating children with obstructive uropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Crossed fused ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In crossed fused ectopy, the ectopic kidney and ureter crosses the midline to fuse with the contralateral kidney but the ureter of the ectopic kidney maintains its normal insertion into the bladder. The estimated incidence from autopsy data is approximately 1 in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the ectopic kidney is positioned inferiorly to the contralateral kidney (",
"    <a class=\"graphic graphic_figure graphicRef60213 \" href=\"UTD.htm?12/30/12771\">",
"     figure 2",
"    </a>",
"    ). The contralateral kidney can either retain its normal dorsolumbar position or is positioned lower in the pelvis or lower lumbar vertebral level (L4 or L5).",
"   </p>",
"   <p>",
"    Most patients with crossed fused ectopy are asymptomatic and are detected coincidentally, often by antenatal ultrasonography. Associated reported anomalies include sacral agenesis, scoliosis, and cardiovascular and gastrointestinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As is true in patients with horseshoe kidney, most patients have an excellent prognosis without need for intervention. In some cases, complications can occur, including obstructive uropathy due to extrinsic ureteric compression by aberrant blood vessels or UPJ obstruction, renal calculi, urinary infection and vesicoureteral reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal ultrasonography can detect the crossed fused ectopic kidney. In symptomatic cases, magnetic resonance urogram is often required to characterize the complete anatomy of the fused kidneys and corresponding ureters. The evaluation and treatment of patients with crossed fused ectopy is similar to that of patients with horseshoe kidneys. If surgery is required, computed tomographic angiography might be needed to characterize vascular anatomy as the vascular supply can be anomalous to both the ectopic and nonectopic kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28487/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal ectopic and fusion anomalies are due to disruption of the normal embryogenic process (",
"      <a class=\"graphic graphic_figure graphicRef68500 \" href=\"UTD.htm?12/41/12948\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal embryogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal ectopy is a positional abnormality with failure of the kidney(s) to normally ascend to the retroperitoneal renal fossa (level of the second lumbar vertebrae). Simple renal ectopy refers to a kidney that lies on the correct side but in an abnormal position and crossed renal ectopy to a kidney that crosses the midline to the contralateral side. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal ectopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal fusion occurs when a portion of one kidney is fused to the other. The most common fusion anomaly is the horseshoe kidney, which involves abnormal migration of both kidneys (ectopy) resulting in fusion (",
"      <a class=\"graphic graphic_figure graphicRef75867 \" href=\"UTD.htm?38/13/39120\">",
"       figure 3",
"      </a>",
"      ). Crossed fused renal ectopia, another renal fusion anomaly, usually involves abnormal movement of only one kidney across the midline with fusion of the contralateral noncrossing kidney (",
"      <a class=\"graphic graphic_figure graphicRef60213 \" href=\"UTD.htm?12/30/12771\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Most patients with an ectopic or fused kidney(s) are asymptomatic and are diagnosed coincidentally, often by antenatal ultrasonography. In patients diagnosed symptomatically with either anomaly, symptoms at presentation are generally related to associated complications including urinary tract infection, obstruction, and renal calculi. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical findings of renal ectopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with renal ectopy or fused kidneys are at increased risk for other anomalies, especially genitourinary abnormalities such as vesicoureteral reflux (VUR). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical findings of renal ectopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation for either renal ectopy or fusion includes the following three studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ultrasonography to demonstrate ectopy or fusion, determine the",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of hydronephrosis, and in patients with renal ectopy assess the renal anatomy of the contralateral kidney.",
"     </li>",
"     <li>",
"      In patients with urinary tract infections, voiding cystourethrogram to determine",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of VUR.",
"     </li>",
"     <li>",
"      if there is evidence of progressive obstruction or bilateral renal disease, serum creatinine to measure renal function.",
"     </li>",
"     <li>",
"      Further evaluation is dependent upon the results of these three initial tests. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation of renal ectopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation of renal fusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/1\">",
"      N'Guessen G, Stephens FD, Pick J. Congenital superior ectopic (thoracic) kidney. Urology 1984; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/2\">",
"      Murphy JJ, Altit G, Zerhouni S. The intrathoracic kidney: should we fix it? J Pediatr Surg 2012; 47:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/3\">",
"      Meizner I, Barnhard Y. Bilateral fetal pelvic kidneys: documentation of two cases of a rare prenatal finding. J Ultrasound Med 1995; 14:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/4\">",
"      Yuksel A, Batukan C. Sonographic findings of fetuses with an empty renal fossa and normal amniotic fluid volume. Fetal Diagn Ther 2004; 19:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/5\">",
"      Sheih CP, Liu MB, Hung CS, et al. Renal abnormalities in schoolchildren. Pediatrics 1989; 84:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/6\">",
"      Guarino N, Tadini B, Camardi P, et al. The incidence of associated urological abnormalities in children with renal ectopia. J Urol 2004; 172:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/7\">",
"      Gupta NP, Goel A, Kumar P, Aron M. Laparoscopy in diagnosis and management of urinary incontinence caused by small ectopic dysplastic kidney. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/8\">",
"      Challacombe B, Kelleher C, Sami T, et al. Laparoscopic nephroureterectomy for adult incontinence caused by functioning ectopic pelvic kidney draining into vagina. J Endourol 2004; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/9\">",
"      Kramer SA, Kelalis PP. Ureteropelvic junction obstruction in children with renal ectopy. J Urol (Paris) 1984; 90:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/10\">",
"      D'Alberton A, Reschini E, Ferrari N, Candiani P. Prevalence of urinary tract abnormalities in a large series of patients with uterovaginal atresia. J Urol 1981; 126:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/11\">",
"      Fedele L, Bianchi S, Agnoli B, et al. Urinary tract anomalies associated with unicornuate uterus. J Urol 1996; 155:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/12\">",
"      Pagon RA, Graham JM Jr, Zonana J, Yong SL. Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr 1981; 99:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/13\">",
"      Evans JA, Stranc LC, Kaplan P, Hunter AG. VACTERL with hydrocephalus: further delineation of the syndrome(s). Am J Med Genet 1989; 34:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/14\">",
"      van den Bosch CM, van Wijk JA, Beckers GM, et al. Urological and nephrological findings of renal ectopia. J Urol 2010; 183:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/15\">",
"      Schulman J, Edmonds LD, McClearn AB, et al. Surveillance for and comparison of birth defect prevalences in two geographic areas--United States, 1983-88. MMWR CDC Surveill Summ 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/16\">",
"      Weizer AZ, Silverstein AD, Auge BK, et al. Determining the incidence of horseshoe kidney from radiographic data at a single institution. J Urol 2003; 170:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/17\">",
"      Friedland GW, de Vries P. Renal ectopia and fusion. Embryologic Basis. Urology 1975; 5:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/18\">",
"      Dom&eacute;nech-Mateu JM, Gonzalez-Compta X. Horseshoe kidney: a new theory on its embryogenesis based on the study of a 16-mm human embryo. Anat Rec 1988; 222:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/19\">",
"      Boatman DL, Cornell SH, K&ouml;lln CP. The arterial supply of horseshoe kidneys. Am J Roentgenol Radium Ther Nucl Med 1971; 113:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/20\">",
"      Odiase VO. Horseshoe kidney. A review of 25 cases. J R Coll Surg Edinb 1983; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/21\">",
"      Segura JW, Kelalis PP, Burke EC. Horseshoe kidney in children. J Urol 1972; 108:333.",
"     </a>",
"    </li>",
"    <li>",
"     Koff SA, Mutabagani KH. Anomalies of the kidney. In: Adult and Pediatric Urology, 3rd ed, Gillenwater JY, Grayhack JT, Howards SS, Mitchell ME (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.2129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/23\">",
"      Raj GV, Auge BK, Assimos D, Preminger GM. Metabolic abnormalities associated with renal calculi in patients with horseshoe kidneys. J Endourol 2004; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/24\">",
"      Evans WP, Resnick MI. Horseshoe kidney and urolithiasis. J Urol 1981; 125:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/25\">",
"      Cascio S, Sweeney B, Granata C, et al. Vesicoureteral reflux and ureteropelvic junction obstruction in children with horseshoe kidney: treatment and outcome. J Urol 2002; 167:2566.",
"     </a>",
"    </li>",
"    <li>",
"     Limowongse C, Cassidy SB. Syndromes and malformations of the urinary tract. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/27\">",
"      Neville H, Ritchey ML, Shamberger RC, et al. The occurrence of Wilms tumor in horseshoe kidneys: a report from the National Wilms Tumor Study Group (NWTSG). J Pediatr Surg 2002; 37:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/28\">",
"      Kao PF, Sheih CP, Tsui KH, et al. The 99mTc-DMSA renal scan and 99mTc-DTPA diuretic renogram in children and adolescents with incidental diagnosis of horseshoe kidney. Nucl Med Commun 2003; 24:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/29\">",
"      GLENN JF. Analysis of 51 patients with horseshoe kidney. N Engl J Med 1959; 261:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/30\">",
"      Pitts WR Jr, Muecke EC. Horseshoe kidneys: a 40-year experience. J Urol 1975; 113:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/31\">",
"      MCDONALD JH, MCCLELLAN DS. Crossed renal ectopia. Am J Surg 1957; 93:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/32\">",
"      Kelalis PP, Malek RS, Segura JW. Observations on renal ectopia and fusion in children. J Urol 1973; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28487/abstract/33\">",
"      Rubinstein ZJ, Hertz M, Shahin N, Deutsch V. Crossed renal ectopia: angiographic findings in six cases. AJR Am J Roentgenol 1976; 126:1035.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6107 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-F4418191A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28487=[""].join("\n");
var outline_f27_52_28487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL EMBRYOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RENAL ECTOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical findings of renal ectopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation of renal ectopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RENAL FUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Horseshoe kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Evaluation of renal fusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Crossed fused ectopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6107|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/54/23393\" title=\"diagnostic image 1\">",
"      CT scan horseshoe kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6107|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/41/12948\" title=\"figure 1\">",
"      Kidney embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12771\" title=\"figure 2\">",
"      Crossed renal ectopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/13/39120\" title=\"figure 3\">",
"      Horseshoe kidney",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=related_link\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/62/41961?source=related_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28488="Furosemide: Drug information";
var content_f27_52_28488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Furosemide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"    see \"Furosemide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"    see \"Furosemide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7305944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lasix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Furosemide&reg;;",
"     </li>",
"     <li>",
"      AVA-Furosemide;",
"     </li>",
"     <li>",
"      Bio-Furosemide;",
"     </li>",
"     <li>",
"      Dom-Furosemide;",
"     </li>",
"     <li>",
"      Furosemide Injection Sandoz Standard;",
"     </li>",
"     <li>",
"      Furosemide Injection, USP;",
"     </li>",
"     <li>",
"      Furosemide Special;",
"     </li>",
"     <li>",
"      Furosemide Special Injection;",
"     </li>",
"     <li>",
"      Lasix&reg;;",
"     </li>",
"     <li>",
"      Lasix&reg; Special;",
"     </li>",
"     <li>",
"      Novo-Semide;",
"     </li>",
"     <li>",
"      NTP-Furosemide;",
"     </li>",
"     <li>",
"      Nu-Furosemide;",
"     </li>",
"     <li>",
"      PMS-Furosemide;",
"     </li>",
"     <li>",
"      Teva-Furosemide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Loop",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema, heart failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 20-80 mg/dose; if response is not adequate, may repeat the same dose or increase dose in increments of 20-40 mg/dose at intervals of 6-8 hours; may be titrated up to 600 mg/day with severe edematous states; usual maintenance dose interval is once or twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing frequency may be adjusted based on patient-specific diuretic needs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial: 20-40 mg/dose; if response is not adequate, may repeat the same dose or increase dose in increments of 20 mg/dose and administer 1-2 hours after previous dose (maximum dose: 200 mg/dose). Individually determined dose should then be given once or twice daily although some patients may initially require dosing as frequent as every 6 hours.",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 guidelines for heart failure recommend a maximum single dose of 160-200 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous I.V. infusion (Howard, 2001; Hunt, 2009):",
"     </i>",
"     Initial: I.V. bolus dose 20-40 mg over 1-2 minutes, followed by continuous I.V. infusion doses of 10-40 mg/hour. If urine output is &lt;1 mL/kg/hour, double as necessary to a maximum of 80-160 mg/hour. The risk associated with higher infusion rates (80-160 mg/hour) must be weighed against alternative strategies.",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 guidelines for heart failure recommend 40 mg I.V. load, then 10-40 mg/hour infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pulmonary edema:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     40 mg over 1-2 minutes. If response not adequate within 1 hour, may increase dose to 80 mg.",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 guidelines for heart failure recommend a maximum single dose of 160-200 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension, resistant (Chobanian, 2003; JNC 7):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     20-80 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory heart failure:",
"     </b>",
"     <i>",
"      Oral, I.V.:",
"     </i>",
"     Doses up to 8 g/day have been used.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F174871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"      see \"Furosemide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema, heart failure:",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 2 mg/kg/dose increased in increments of 1-2 mg/kg/dose with each succeeding dose at intervals of 6-8 hours until a satisfactory response is achieved; maximum dose: 6 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Initial: 1 mg/kg/dose; if response not adequate, may increase dose in increments of 1 mg/kg/dose and administer not sooner than 2 hours after previous dose, until a satisfactory response is achieved; may administer maintenance dose at intervals of every 6-12 hours; maximum dose: 6 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension, resistant (unlabeled; AAP, 2004):",
"     </b>",
"     Children 1-17 years:",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 0.5-2 mg/kg/dose once or twice daily; maximum dose: 6 mg/kg/dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.M., I.V.: Initial: 20 mg/day; increase slowly to desired response.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute renal failure: Doses up to 1-3 g/day may be necessary to initiate desired response; avoid use in oliguric states.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis. Monitor effects, particularly with high doses.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (2 mL, 4 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 40 mg/5 mL (5 mL, 500 mL); 10 mg/mL (4 mL, 60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lasix&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lasix&reg;: 40 mg, 80 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13262443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Furosemide Special Injection: 10 mg/mL (25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lasix&reg; Special: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: I.V. injections should be given slowly. In adults, undiluted direct I.V. injections may be administered at a rate of 20-40 mg per minute; maximum rate of administration for short-term intermittent infusion is 4 mg/minute; exceeding this rate increases the risk of ototoxicity. In children, a maximum rate of 0.5 mg/kg/minute has been recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer on an empty stomach (Bard, 2004). May be administered with food or milk if GI distress occurs; however, this may reduce diuretic efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When I.V. or oral administration is not possible, the sublingual route may be used. Place 1 tablet under tongue for at least 5 minutes to allow for maximal absorption. Patients should be advised not to swallow during disintegration time (Haegeli, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"     <b>",
"      or",
"     </b>",
"     2 mg/mL",
"     <b>",
"      or",
"     </b>",
"     undiluted as 10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"     <b>",
"      or",
"     </b>",
"     2 mg/mL",
"     <b>",
"      or",
"     </b>",
"     undiluted as 10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, mannitol 20%, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, alprostadil, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, argatroban, aztreonam, bivalirudin, bleomycin, calcium gluconate, cefepime, ceftazidime, cefuroxime, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin liposome, epinephrine, etoposide phosphate, fentanyl, fludarabine, fluorouracil, foscarnet, gallium nitrate, granisetron, heparin, hetastarch in lactated electrolyte (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, indomethacin, insulin (regular), leucovorin calcium, linezolid, lorazepam, magnesium sulfate, melphalan, meropenem, methotrexate, micafungin, mitomycin, nitroprusside, norepinephrine, oxaliplatin, paclitaxel, piperacillin/tazobactam, potassium chloride, procainamide, propofol, ranitidine, remifentanil, sargramostim, sodium bicarbonate, tacrolimus, teniposide, thiopental, thiotepa, tirofiban, tobramycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amsacrine, azithromycin, caffeine citrate, caspofungin, chlorpromazine, ciprofloxacin, diltiazem, droperidol, eptifibatide, esmolol, fenoldopam, filgrastim, fluconazole, gemcitabine, gentamicin, haloperidol, hydralazine, idarubicin, labetalol, levofloxacin, methocarbamol, metoclopramide, midazolam, milrinone, nesiritide, nicardipine, ondansetron, phenylephrine, promethazine, quinidine gluconate, telavancin, vecuronium, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amikacin, amiodarone, cisatracurium, dobutamine, dopamine, doxorubicin HCl, drotrecogin alfa, famotidine, kanamycin, meperidine, metoprolol, morphine, nitroglycerin, pantoprazole, vasopressin, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, dexamethasone sodium phosphate, fluorouracil, heparin, leucovorin calcium, methotrexate, mitomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, diphenhydramine, dimenhydrinate, doxapram, doxorubicin HCl, droperidol, meperidine, metoclopramide, milrinone, pantoprazole, protamine, thiamine, vinblastine, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with heart failure and hepatic or renal disease; acute pulmonary edema; treatment of hypertension (alone or in combination with other antihypertensives)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use: Furosemide Special Injection and Lasix&reg; Special (products not available in the U.S.): Adjunctive treatment of oliguria in patients with severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Furosemide may be confused with famotidine, finasteride, fluconazole, FLUoxetine, fosinopril, loperamide, torsemide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lasix&reg; may be confused with Lanoxin&reg;, Lidex&reg;, Lomotil&reg;, Lovenox&reg;, Luvox&reg;, Luxiq&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lasix [U.S., Canada, and multiple international markets] may be confused with Esidrex brand name for hydrochlorothiazide [multiple international markets]; Esidrix brand name for hydrochlorothiazide [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex [Australia, Hong Kong, Turkey] may be confused with Eurax brand name for crotamiton [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Acute hypotension, chronic aortitis, necrotizing angiitis, orthostatic hypotension, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, hepatic encephalopathy, lightheadedness,  restlessness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bullous pemphigoid, cutaneous vasculitis, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, exanthematous pustulosis (generalized), exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol and triglycerides increased, glucose tolerance test altered, gout, hyperglycemia, hyperuricemia, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, cramping, diarrhea, nausea, oral and gastric irritation, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary bladder spasm, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematological: Agranulocytosis (rare), anemia, aplastic anemia (rare), eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Intrahepatic cholestatic jaundice, ischemic hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain (following I.M. injection), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing impairment (reversible or permanent with rapid I.V. or I.M. administration), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Allergic interstitial nephritis, fall in glomerular filtration rate and renal blood flow (due to overdiuresis), glycosuria, transient rise in BUN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (rare), exacerbate or activate systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to furosemide or any component of the formulation; anuria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to sulfonamide-derived drugs; complete renal shutdown; hepatic coma and precoma; uncorrected states of electrolyte depletion, hypovolemia, or hypotension; jaundiced newborn infants or infants with disease(s) capable of causing hyperbilirubinemia and possibly kernicterus; breast-feeding.",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer labeling for Lasix&reg; Special and Furosemide Special Injection also includes: GFR &lt;5 mL/minute or GFR &gt;20 mL/minute; hepatic cirrhosis; renal failure accompanied by hepatic coma and precoma; renal failure due to poisoning with nephrotoxic or hepatotoxic substances.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss:",
"     <b>",
"      [U.S. Boxed Warning]: If given in excessive amounts, furosemide, similar to other loop diuretics, can lead to profound diuresis, resulting in fluid and electrolyte depletion.",
"     </b>",
"     Close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. When electrolyte depletion is present, therapy should not be initiated unless serum electrolytes, especially potassium, are normalized. Risk of hypokalemia may be increased by: rapid diuresis, poor oral potassium intake, cirrhosis, and combined use with large amounts of licorice, corticosteroids, or laxatives (chronic use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperuricemia: Asymptomatic hyperuricemia has been reported with use; rarely, gout may precipitate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required. May increase risk of radiocontrast-induced nephropathy in high-risk patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity: Rapid I.V. administration, renal impairment, excessive doses, hypoproteinemia, and concurrent use of other ototoxins is associated with ototoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). A risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy; correct electrolyte and acid/base imbalances prior to initiation when hepatic coma is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: May cause urinary retention due to increased urine production, especially upon initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): May cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Coadministration of antihypertensives may increase the risk of hypotension; reduction in antihypertensive dosage may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Diuretic-induced hypokalemia may potentiate digoxin-related cardiac toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May lead to nephrocalcinosis or nephrolithiasis in premature infants or in children &lt;4 years of age with chronic use. May prevent closure of patent ductus arteriosus in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Loop Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May decrease the serum concentration of Furosemide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. This by increasing the risk of hypokalemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloral Hydrate: Furosemide may enhance the adverse/toxic effect of Chloral Hydrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethacrynic Acid: Furosemide may enhance the ototoxic effect of Ethacrynic Acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Loop Diuretics may diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Methotrexate may increase the serum concentration of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F174837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Furosemide serum levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may increase antihypertensive effect). Licorice may also cause or worsen hypokalemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated maternal death, fetal toxicity, and fetal loss. There are no adequate and well-controlled studies in pregnant women. Crosses the placenta. Increased fetal urine production, electrolyte disturbances reported. Generally, use of diuretics during pregnancy is avoided due to risk of decreased placental perfusion. Monitor fetal growth if used during pregnancy; may increase birth weight.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F174824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Crosses into breast milk; may suppress lactation",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F174825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause potassium loss; potassium supplement or dietary changes may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F174822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Furosemide Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (4 mL): $2.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Furosemide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (5 mL): $1.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (60 mL): $10.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Furosemide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $14.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $16.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $43.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lasix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $47.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $66.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (50): $53.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor weight and I &amp; O daily; blood pressure, orthostasis; serum electrolytes, renal function; monitor hearing with high doses or rapid I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A Xi Ya (CL);",
"     </li>",
"     <li>",
"      A-Basedock (JP);",
"     </li>",
"     <li>",
"      Accent (JP);",
"     </li>",
"     <li>",
"      Ai Ge (CL);",
"     </li>",
"     <li>",
"      Akoset (MY);",
"     </li>",
"     <li>",
"      Anfuramide (JP);",
"     </li>",
"     <li>",
"      Aquarid (ZA);",
"     </li>",
"     <li>",
"      Arasemide (JP);",
"     </li>",
"     <li>",
"      Daiteren F (JP);",
"     </li>",
"     <li>",
"      Depix (JP);",
"     </li>",
"     <li>",
"      Desal (PL);",
"     </li>",
"     <li>",
"      Dirine (MY);",
"     </li>",
"     <li>",
"      Disemide (TW);",
"     </li>",
"     <li>",
"      Diural (DK, NO, SE);",
"     </li>",
"     <li>",
"      Diuresal (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Diurin (NZ);",
"     </li>",
"     <li>",
"      Diusemide (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Diuvar (ID);",
"     </li>",
"     <li>",
"      Dryptal (IE);",
"     </li>",
"     <li>",
"      Edemid (HR);",
"     </li>",
"     <li>",
"      Errolon (AR);",
"     </li>",
"     <li>",
"      Femide 500 (TH);",
"     </li>",
"     <li>",
"      Foliront (JP);",
"     </li>",
"     <li>",
"      Fretic (PH);",
"     </li>",
"     <li>",
"      Frusedan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Frusid (AU, HK, NZ);",
"     </li>",
"     <li>",
"      Fulsix (JP);",
"     </li>",
"     <li>",
"      Fuluvamide (JP);",
"     </li>",
"     <li>",
"      Furanthril (CZ);",
"     </li>",
"     <li>",
"      Furanturil (BG);",
"     </li>",
"     <li>",
"      Furesin (BR);",
"     </li>",
"     <li>",
"      Furetic (TH);",
"     </li>",
"     <li>",
"      Furide (TW);",
"     </li>",
"     <li>",
"      Furix (NO, SE);",
"     </li>",
"     <li>",
"      Furo-Puren (DE);",
"     </li>",
"     <li>",
"      Furolink (PH);",
"     </li>",
"     <li>",
"      Furomen (FI);",
"     </li>",
"     <li>",
"      Furomex (CZ);",
"     </li>",
"     <li>",
"      Furomin (FI);",
"     </li>",
"     <li>",
"      Furon (HU);",
"     </li>",
"     <li>",
"      Furorese (DE, LU);",
"     </li>",
"     <li>",
"      Furosedon (JP);",
"     </li>",
"     <li>",
"      Furosemid (HR, HU);",
"     </li>",
"     <li>",
"      Furosemid Pharmavit (HU);",
"     </li>",
"     <li>",
"      Furosemid-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Furosemide-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Furosemix (LU);",
"     </li>",
"     <li>",
"      Fursemid (HR);",
"     </li>",
"     <li>",
"      Fursemid[inj.] (HR);",
"     </li>",
"     <li>",
"      Furusemide (JP);",
"     </li>",
"     <li>",
"      Fuseride (TH);",
"     </li>",
"     <li>",
"      Fusid (DE, IL);",
"     </li>",
"     <li>",
"      Fusimex (PH);",
"     </li>",
"     <li>",
"      Glosix (ID);",
"     </li>",
"     <li>",
"      Impugan (DK, ID, SE);",
"     </li>",
"     <li>",
"      Indiurex (PH);",
"     </li>",
"     <li>",
"      Jufurix (DE);",
"     </li>",
"     <li>",
"      Katlex (JP);",
"     </li>",
"     <li>",
"      Kutrix (JP);",
"     </li>",
"     <li>",
"      Lasilix (FR, MA);",
"     </li>",
"     <li>",
"      Lasix (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EG, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, ID, IE, IN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Lasix Retard (DK, EE, NO, PT, SE);",
"     </li>",
"     <li>",
"      Lasix[inj.] (HR);",
"     </li>",
"     <li>",
"      Lowpston (JP);",
"     </li>",
"     <li>",
"      Luseck (JP);",
"     </li>",
"     <li>",
"      Maoread (JP);",
"     </li>",
"     <li>",
"      Naclex (ID);",
"     </li>",
"     <li>",
"      Nadis (TW);",
"     </li>",
"     <li>",
"      Nephron (AR);",
"     </li>",
"     <li>",
"      Odemase (DE);",
"     </li>",
"     <li>",
"      Odemex (CR, DO, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Oedemex (AE, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pharmix (PH);",
"     </li>",
"     <li>",
"      Promedes (JP);",
"     </li>",
"     <li>",
"      Radisemide (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Radouna (JP);",
"     </li>",
"     <li>",
"      Rasitol (MY, PH, SG);",
"     </li>",
"     <li>",
"      Retep (AR);",
"     </li>",
"     <li>",
"      Salinex (IN);",
"     </li>",
"     <li>",
"      Seguril (ES);",
"     </li>",
"     <li>",
"      Silax (ID);",
"     </li>",
"     <li>",
"      Synephron (JP);",
"     </li>",
"     <li>",
"      Trofurit (HU);",
"     </li>",
"     <li>",
"      Uremide (AU, NZ);",
"     </li>",
"     <li>",
"      Uresix (ID);",
"     </li>",
"     <li>",
"      Urex (HK, JP);",
"     </li>",
"     <li>",
"      Urex Forte (HK);",
"     </li>",
"     <li>",
"      Urex-M (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: Oral, S.L: 30-60 minutes; I.M.: 30 minutes; I.V.: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symptomatic improvement with acute pulmonary edema: Within 15-20 minutes; occurs prior to diuretic effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral, S.L.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral, S.L.: 6-8 hours; I.V.: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 91% to 99%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral tablet: 47% to 64%; Oral solution: 50%; S.L. administration of oral tablet: ~60%; results of a small comparative study (n=11) showed bioavailability of S.L. administration of tablet was ~12% higher than oral administration of tablet (Haegeli, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 0.5-2 hours; End-stage renal disease: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (Oral: 50%, I.V.: 80%) within 24 hours; feces (as unchanged drug); nonrenal clearance prolonged in renal impairment",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bard RL, Bleske BE, and Nicklas JM, &ldquo;Food: An Unrecognized Source of Loop Diuretic Resistance,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(5):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/15162897/pubmed\" id=\"15162897\" target=\"_blank\">",
"        15162897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown CB, Ogg CS, and Cameron JS, &ldquo;High-Dose Frusemide in Acute Renal Failure: A Controlled Trial,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(2):90-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/7011622/pubmed\" id=\"7011622\" target=\"_blank\">",
"        7011622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chaudhry AY, Bing RF, Castleden CM, et al, &ldquo;The Effect of Aging on the Response to Frusemide in Normal Subjects,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1984, 27(3):303-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/6391935/pubmed\" id=\"6391935\" target=\"_blank\">",
"        6391935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Felker GM, Lee KL, Bull DA, et al, \"Diuretic Strategies in Patients With Acute Decompensated Heart Failure,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(9):797-805.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/21366472/pubmed\" id=\"21366472\" target=\"_blank\">",
"        21366472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerlag PG and van Meijel JJ, &ldquo;High-Dose Furosemide in the Treatment of Refractory Congestive Heart Failure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1988, 148(2):286-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/3341836/pubmed\" id=\"3341836\" target=\"_blank\">",
"        3341836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haegeli L, Brunner-La Rocca HP, Wenk M, et al, &ldquo;Sublingual Administration of Furosemide: New Application of an Old Drug,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(6):804-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/17875188/pubmed\" id=\"17875188\" target=\"_blank\">",
"        17875188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howard PA and Dunn MI, &ldquo;Aggressive Diuresis for Severe Heart Failure in the Elderly,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 119(3):807-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/11243961/pubmed\" id=\"11243961\" target=\"_blank\">",
"        11243961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuchar DL and O'Rourke MF, &ldquo;High Dose Furosemide in Refractory Cardiac Failure,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1985, 6(11):954-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/4076205/pubmed\" id=\"4076205\" target=\"_blank\">",
"        4076205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudy DW, Voelker JR, Greene PK, et al, &ldquo;Loop Diuretics for Chronic Renal Insufficiency: A Continuous Infusion Is More Efficacious Than Bolus Therapy,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 115(5):360-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/1863026/pubmed\" id=\"1863026\" target=\"_blank\">",
"        1863026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Runyon BA, &ldquo;Management of Adult Patients With Ascites Due to Cirrhosis: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(6):2087-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/19475696/pubmed\" id=\"19475696\" target=\"_blank\">",
"        19475696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuller D, Lynch JP, and Fine D, &ldquo;Protocol-Guided Diuretic Management: Comparison of Furosemide by Continuous Infusion and Intermittent Bolus,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1997, 25(12):1969-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/52/28488/abstract-text/9403744/pubmed\" id=\"9403744\" target=\"_blank\">",
"        9403744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8482 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28488=[""].join("\n");
var outline_f27_52_28488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305944\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174841\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174842\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174893\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174846\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174871\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174847\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174848\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174849\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174813\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13262443\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174798\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174817\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472639\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472640\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174900\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174816\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174902\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174891\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174820\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174802\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299370\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174807\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174837\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174809\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174823\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174855\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174824\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174825\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174822\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174811\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174826\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174801\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174819\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8482|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=related_link\">",
"      Furosemide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=related_link\">",
"      Furosemide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28489="Endoscopy in patients who have undergone bariatric surgery";
var content_f27_52_28489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopy in patients who have undergone bariatric surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Christopher S Huang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28489/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28489/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/52/28489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of bariatric weight loss surgery is escalating in response to the obesity epidemic, with multiple surgical procedures being available. Bariatric surgical procedures currently performed in the United States include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Roux-en-Y gastric bypass (",
"      <a class=\"graphic graphic_figure graphicRef79256 \" href=\"UTD.htm?32/35/33329\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vertical banded gastroplasty (",
"      <a class=\"graphic graphic_figure graphicRef57137 \" href=\"UTD.htm?35/28/36303\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laparoscopic adjustable gastric banding (",
"      <a class=\"graphic graphic_figure graphicRef60081 \" href=\"UTD.htm?21/54/22368\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sleeve gastrectomy (",
"      <a class=\"graphic graphic_figure graphicRef54612 \" href=\"UTD.htm?35/40/36480\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sleeve gastrectomy with duodenal switch (",
"      <a class=\"graphic graphic_figure graphicRef54159 \" href=\"UTD.htm?19/33/19987\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, many of the complications following bariatric surgery were managed with reoperation, which was often associated with significant morbidity. In many cases, therapeutic endoscopy permits a less invasive approach to the treatment of postsurgical complications. As a result, gastrointestinal endoscopists are becoming increasingly involved in the care of bariatric surgery patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the role of endoscopy in patients who have undergone bariatric surgery, highlighting the endoscopic management of gastrointestinal complications of the most common bariatric surgical procedures. The following discussion is generally consistent with the 2008 American Society for Gastrointestinal Endoscopy (ASGE) Standards for Practice Committee guidelines on the role of endoscopy in the bariatric surgery patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the various bariatric procedures, radiographic imaging after bariatric surgery, and the complications of bariatric surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link\">",
"     \"Imaging studies after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy plays an important role in the evaluation and management of postoperative upper gastrointestinal (GI) symptoms and complications following bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Commonly encountered symptoms include abdominal pain, nausea, vomiting, and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Less common symptoms include weight regain, heartburn, regurgitation, hematemesis, and melena. The etiology of these symptoms can be multifactorial and frequently involves noncompliance with prescribed food choices and eating behaviors.",
"   </p>",
"   <p>",
"    An evaluation with endoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic imaging is warranted to identify a source and exclude structural complications in patients with GI bleeding, biliary obstruction, or symptoms that persist despite counseling and behavior modification. Endoscopy has the added benefit of potentially providing therapy. Evaluation is particularly important in patients who present within the first three to six postoperative months, since this is when the majority of postoperative complications occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Abnormal endoscopic findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREPARATION FOR ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopists should adhere to the following general principles when performing endoscopy in bariatric surgery patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be familiar with the specific surgical procedure performed and the expected postsurgical anatomy. Operative reports should be reviewed, and direct communication with the surgeon is advisable whenever possible.",
"     </li>",
"     <li>",
"      Review all relevant postoperative imaging studies.",
"     </li>",
"     <li>",
"      Select the appropriate endoscopic equipment and accessories based upon the indication for the procedure and information gathered from the above investigations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other considerations include the sedation and analgesia plan, and the appropriate venue for the procedure (ie, endoscopy suite versus operating room). These decisions should take into account the patient's comorbidities, the acuity and severity of the postoperative complication, and the complexity of the planned endoscopic procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of endoscope and accessories is determined by the indication for the procedure, the likely need for therapeutic intervention, and the patient's postsurgical anatomy (",
"    <a class=\"graphic graphic_table graphicRef54031 \" href=\"UTD.htm?2/41/2717\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A standard upper endoscope can be used to evaluate patients following purely restrictive procedures such as vertical banded gastroplasty and laparoscopic adjustable gastric banding. This also applies to Roux-en-Y gastric bypass (RYGB) cases in which the gastric pouch or the proximal Roux limb is being examined. However, a pediatric colonoscope or enteroscope may be needed to examine the jejunojejunal anastomosis, depending upon the length of the Roux limb.",
"   </p>",
"   <p>",
"    Retrograde evaluation of the biliopancreatic limb and bypassed stomach is challenging in patients who have undergone RYGB, but can be accomplished in some cases with a pediatric colonoscope or an enteroscope [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The use of a ShapeLock&trade; enteroscopy guide (USGI Medical, Inc, San Clemente, California) to facilitate intubation of the bypassed stomach has been described in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deep small bowel enteroscopy has been used to examine the bypassed stomach in patients who have undergone RYGB. The reported success rates have been as high as 88 percent, even in patients who have undergone long limb (up to 150 cm) RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Methods for deep small bowel enteroscopy include double balloon enteroscopy, single balloon enteroscopy, and spiral enteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link\">",
"     \"Overview of deep small bowel enteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Balloon-assisted enteroscopy uses balloons attached to an overtube with or without a balloon at the tip of the enteroscope. The balloons anchor the enteroscope and overtube as the enteroscope is advanced through the small bowel. With spiral enteroscopy, a spiral overtube is placed over the enteroscope. As the spiral is rotated, the small bowel is \"pulled\" onto the overtube, advancing the enteroscope through the small bowel.",
"   </p>",
"   <p>",
"    Deep small bowel enteroscopy can also facilitate the performance of endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y anatomy. However, this technique is not widely available outside of specialty centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"     \"ERCP in patients with Roux-en-Y anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXPECTED FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Roux-en-Y gastric bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expected endoscopic findings after RYGB (",
"    <a class=\"graphic graphic_figure graphicRef79256 \" href=\"UTD.htm?32/35/33329\">",
"     figure 1",
"    </a>",
"    ) include a normal esophagus and gastroesophageal junction (GEJ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H17#H17\">",
"     \"Surgical management of severe obesity\", section on 'Roux-en-Y gastric bypass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the stomach is limited to the gastric pouch, which varies in size, but is typically short (approximately 5 cm long) and has a small volume (less than 30 mL). The gastrojejunal anastomosis, or stoma, is generally 10 to 12 mm in diameter and should easily permit the passage of a diagnostic endoscope without resistance (",
"    <a class=\"graphic graphic_picture graphicRef58276 \" href=\"UTD.htm?6/53/6992\">",
"     picture 1",
"    </a>",
"    ). Distal to the anastomosis is a short, blind limb of jejunum alongside the efferent Roux limb, resulting in a \"shepherd's hook\" configuration. The length of the Roux limb is variable, now typically ranging from 100 to 150 cm. However, in the \"distal bypass\" modification, the Roux limb is extremely long, as the biliopancreatic limb is connected to the ileum approximately 150 cm proximal to the ileocecal valve. It is important that the endoscopist carefully review the operative report",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speak with the surgeon in the setting of &ldquo;distal&rdquo; gastric bypass, as there can be considerable variation in the limb lengths between surgeons and centers.",
"   </p>",
"   <p>",
"    The endoscopic findings in the bypassed stomach have not been well characterized due to technical difficulties in reaching the bypassed stomach. Based upon studies using double balloon enteroscopy, the majority of bypassed stomachs demonstrate gastritis (erosive, erythematous, atrophic, or hemorrhagic), even in patients with a normal preoperative endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The clinical significance of the gastritis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vertical banded gastroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscopic findings after VBG include a normal esophagus and gastroesophageal junction (GEJ), followed by a vertically-oriented pouch along the lesser curvature of the stomach (",
"    <a class=\"graphic graphic_figure graphicRef57137 \" href=\"UTD.htm?35/28/36303\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H27#H27\">",
"     \"Surgical management of severe obesity\", section on 'Vertical banded gastroplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The banded stoma at the distal end of the pouch is typically 7 to 8 cm distal to the GEJ and approximately 10 to 12 mm in diameter. Once traversed, the unaltered distal stomach and duodenum can be examined in the usual manner. Retroflexion of the endoscope within the distal stomach reveals the gastric partition and greater curvature (",
"    <a class=\"graphic graphic_picture graphicRef74191 \" href=\"UTD.htm?16/21/16721\">",
"     picture 2",
"    </a>",
"    ), and the scope tip can be \"pulled in\" to examine the gastric fundus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laparoscopic adjustable gastric banding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic gastric banding (LAGB) is a purely restrictive procedure that compartmentalizes the upper stomach by placing a tight, adjustable prosthetic band around the entrance to the stomach (",
"    <a class=\"graphic graphic_figure graphicRef60081 \" href=\"UTD.htm?21/54/22368\">",
"     figure 3",
"    </a>",
"    ). Endoscopy reveals a variable degree of extrinsic, circumferential compression on the proximal",
"    <span class=\"nowrap\">",
"     stomach/gastric",
"    </span>",
"    cardia, usually within a few centimeters of the GEJ (",
"    <a class=\"graphic graphic_picture graphicRef56233 \" href=\"UTD.htm?28/12/28865\">",
"     picture 3",
"    </a>",
"    ). The remainder of the upper gastrointestinal tract should appear normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H22#H22\">",
"     \"Surgical management of severe obesity\", section on 'Laparoscopic adjustable gastric banding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sleeve gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleeve gastrectomy results in a long, tubular conduit along the lesser curvature of the stomach (",
"    <a class=\"graphic graphic_figure graphicRef54612 \" href=\"UTD.htm?35/40/36480\">",
"     figure 4",
"    </a>",
"    ). A duodenal switch is frequently performed in conjunction with sleeve gastrectomy, which creates a duodenoileal anastomosis visible just distal to the intact gastric pylorus (",
"    <a class=\"graphic graphic_figure graphicRef54159 \" href=\"UTD.htm?19/33/19987\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H23#H23\">",
"     \"Surgical management of severe obesity\", section on 'Sleeve gastrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ABNORMAL ENDOSCOPIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various complications may be seen on endoscopy following Roux-en-Y gastric bypass (RYGB), vertical banded gastroplasty (VBG), laparoscopic adjustable gastric banding (LAGB), duodenal switch, and sleeve gastrectomy.",
"   </p>",
"   <p>",
"    These include the following, all of which are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stomal stenosis",
"     </li>",
"     <li>",
"      Stomal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pouch dilation",
"     </li>",
"     <li>",
"      Gastrogastric fistula",
"     </li>",
"     <li>",
"      Band erosion",
"     </li>",
"     <li>",
"      Unraveled suture material",
"     </li>",
"     <li>",
"      Esophageal dilation",
"     </li>",
"     <li>",
"      Marginal ulcers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Predictors of abnormal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parameters that are predictive of abnormal endoscopic findings include the symptoms reported, the time since the patient's surgery, and patient-related risk factors and exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 45 percent of RYGB patients who undergo diagnostic endoscopy for evaluation of symptoms have normal postsurgical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Symptoms that have been associated with abnormal endoscopic findings include dysphagia, nausea, vomiting, and upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Time since surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the longer the interval since surgery, the greater the likelihood of a patient having a normal endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4,6\">",
"     4,6",
"    </a>",
"    ], with the possible exception of patients with staple line dehiscences, who more frequently present later in the postoperative course. In a study of 49 symptomatic patients, 85 percent had abnormal endoscopic findings within the first six postoperative months compared with 47 percent of patients evaluated after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stomal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal stenosis should be suspected in patients who present with nausea, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ]. However, the positive predictive value of these symptoms for stomal stenosis is only 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/4\">",
"     4",
"    </a>",
"    ]. The absence of these symptoms essentially rules out the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H29#H29\">",
"     \"Complications of bariatric surgery\", section on 'Stomal stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stomal stenoses typically occur within three to six months following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,7,18-20\">",
"     6,7,18-20",
"    </a>",
"    ]. The time course was illustrated in a prospective study of 400 RYGB patients who underwent routine endoscopy (ie, regardless of symptoms) following surgery at one month and again after a mean of 17 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/21\">",
"     21",
"    </a>",
"    ]. Stomal stenoses were diagnosed and treated in 25 percent of patients at one month and in none of the patients at the second examination. The majority of stenoses were mild (stomal diameter of 7 to 9 mm), and nearly 30 percent of patients with stomal stenosis were asymptomatic.",
"   </p>",
"   <p>",
"    Stomal stenosis is diagnosed when there is resistance to the passage of a standard diagnostic upper endoscope through the gastrojejunal anastomosis with RYGB or the pouch outlet with VBG (",
"    <a class=\"graphic graphic_picture graphicRef74282 \" href=\"UTD.htm?16/39/17008\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Endoscopic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic dilation is first-line treatment for stomal stenosis in most patients with RYGB because endoscopic dilation using through-the-scope (TTS) balloons or wire-guided bougie dilators is safe and highly effective. The majority of cases can be successfully treated within one to three dilation sessions, and surgical revision is rarely necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,18,22,23\">",
"     6,18,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal technique remains to be determined. TTS balloon dilators are generally preferred given their ease of use, safety, and the ability to perform multiple dilations under direct endoscopic visualization without the need to repeatedly intubate the esophagus.",
"   </p>",
"   <p>",
"    The primary goal of dilation therapy is symptom resolution, which can usually be attained at a stomal diameter of 10 to 12 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,24\">",
"     6,24",
"    </a>",
"    ]. The size of the balloon or bougie used to perform dilation therapy should be guided by factors such as the severity of the stenosis, the time since surgery, the size of the initial anastomosis, and the presence of marginal ulceration. Most recent studies describing the use of balloon dilators in this setting have utilized balloons ranging from 10 to 18 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,18-20,22-25\">",
"     6,18-20,22-25",
"    </a>",
"    ], with some suggesting an optimal goal of 15 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very tight stenoses should be gradually dilated over multiple sessions using progressively larger dilators and generally adhering to the \"rule of threes\" (ie, dilating no more than 3 mm or 3 Fr sizes in a single session) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/26\">",
"     26",
"    </a>",
"    ]. Endoscopists should exercise caution when attempting to pass a balloon dilator beyond a tight stenosis after RYGB because of the short blind stump of jejunum immediately (and sometimes directly) beyond the gastrojejunal anastomosis. In these situations, guidewire-assisted",
"    <span class=\"nowrap\">",
"     balloon/bougie",
"    </span>",
"    dilation under fluoroscopic guidance may be necessary.",
"   </p>",
"   <p>",
"    Additional techniques that may improve the effectiveness and durability of dilation therapy for stomal stenosis include glucocorticoid injection and the removal of suture material at the site of the stenosis, although the benefit of these maneuvers has not been studied rigorously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. Short-term stenting has also been used to successfully treat stomal stenoses that are refractory to repeated dilation sessions, but complications such as pain and stent migration are common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/27\">",
"     27",
"    </a>",
"    ]. In rare instances, needle-knife electrocautery incision can be used to cut open a completely obstructed stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perforation has been reported in up to 2 to 3 percent of patients undergoing dilation for stomal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. The risk can be minimized by starting with a dilator that is only slightly larger than the diameter of the stoma and increasing the size gradually. Avoidance of overly aggressive dilation will also reduce the risk of creating an excessively large stoma, which can potentially contribute to weight regain and dumping syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stomal and/or pouch dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight regain after bariatric surgery can be attributed to several mechanisms, most commonly a lack of compliance with programmatic diet and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. An excessively wide stoma or dilated pouch may contribute to weight regain after RYGB or VBG surgery by allowing more liberal food intake, although the significance of these findings, particularly stomal dilation, remains a matter of debate. A dilated stoma may also contribute to postprandial dumping syndrome by allowing rapid passage of food into the small bowel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H28#H28\">",
"     \"Complications of bariatric surgery\", section on 'Gastric remnant distension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H39#H39\">",
"     \"Complications of bariatric surgery\", section on 'Failure to lose weight and weight regain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H35#H35\">",
"     \"Complications of bariatric surgery\", section on 'Dumping syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Endoscopic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic reduction of dilated stomas and pouches has been attempted using sclerosants and suturing devises. Injecting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"     sodium morrhuate",
"    </a>",
"    circumferentially around the stoma has been used to induce fibrosis and tissue retraction. In a series of 28 RYGB patients, this relatively simple technique resulted in the successful reduction of the stomal diameter to 12 mm or less along with a loss of 75 percent or more of regained weight in 18 patients (64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients underwent a mean of 2.3 treatment sessions, resulting in an average decrease in stoma diameter from 17 mm to 13 mm, with an average weight loss of 22 kg.",
"   </p>",
"   <p>",
"    A successful reduction of stomal diameter with subsequent weight loss can also be achieved using endoscopic suturing devices, although this is a technically challenging technique with questionable long-term durability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A pilot study demonstrated the successful reduction of enlarged gastric pouches and stomas in 17 of 20 RYGB patients using a novel endoscopic suturing and full-thickness tissue plicating platform [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/33\">",
"     33",
"    </a>",
"    ]. The average weight loss after a technically successful procedure was 9 kg at three months, compared with an average weight gain of 5 kg in the patients in whom plications could not be placed. Long-term follow-up data are awaited.",
"   </p>",
"   <p>",
"    In addition to possibly helping with weight loss, a reduction of the stoma may also benefit patients with intractable dumping syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fistulae and leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrogastric fistulae, gastrocutaneous fistulae, and gastric leaks can result from staple line dehiscence or an incomplete division of the stomach during pouch creation. Complications of gastrogastric fistulae in patients who have undergone RYGB or VBG include weight regain, marginal ulcers, and heartburn. While a large dehiscence or fistula is easily identified and may even allow passage of the endoscope into the",
"    <span class=\"nowrap\">",
"     bypassed/defunctionalized",
"    </span>",
"    segment (",
"    <a class=\"graphic graphic_picture graphicRef61484 \" href=\"UTD.htm?42/3/43057\">",
"     picture 5",
"    </a>",
"    ), a small dehiscence or fistula may have the appearance of a small diverticulum and can be easily overlooked. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H39#H39\">",
"     \"Complications of bariatric surgery\", section on 'Failure to lose weight and weight regain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Endoscopic closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic approaches to correcting gastrogastric fistulae, gastrocutaneous fistulae, gastric leaks, and staple line dehiscences have generally employed a combination of endoscopic suturing, hemoclips, covered stents, and fibrin glue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Long-term durability of endoscopic suturing techniques has been disappointing, especially for larger defects, and a standardized technique has not been established.",
"   </p>",
"   <p>",
"    A pilot study using a novel permanent full-thickness tissue apposition system in combination with mucosectomy produced a successful closure of five gastrogastric fistulae in four RYGB patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/38\">",
"     38",
"    </a>",
"    ]. However, only 20 percent remained closed at three months, and none were closed at six months.",
"   </p>",
"   <p>",
"    There is accumulating experience with the off-label use of covered esophageal self-expanding metal stents (SEMS) or self-expanding plastic stents (SEPS) to treat acute leaks and chronic gastrogastric fistulae complicating bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/27,39-43\">",
"     27,39-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 21 patients (eight RYGB, eight sleeve gastrectomy with duodenal switch, four sleeve gastrectomy alone, one biliopancreatic diversion) underwent stent therapy for large anastomotic leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/39\">",
"       39",
"      </a>",
"      ]. Stent therapy alone resulted in primary closure in 13 of 21 patients (62 percent) after a median of 62 days (range 35-214).",
"     </li>",
"     <li>",
"      A second study involved 19 patients with anastomotic complications after RYGB or sleeve gastrectomy, 11 of whom had acute leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/27\">",
"       27",
"      </a>",
"      ]. Stent therapy achieved healing rates of 89 percent of acute leaks after a mean of 33 days and allowed immediate oral nutrition in 65 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of stent therapy include stent migration, gastrointestinal bleeding, and pain. In addition, tissue hyperplasia within the interstices of the uncovered portions of SEMS can make subsequent stent removal difficult and traumatic. Although temporary stenting appears to offer a promising alternative to major revisional surgery for anastomotic leaks and fistulae, firm conclusions cannot be drawn yet regarding safety, effectiveness, and optimal treatment protocol.",
"   </p>",
"   <p>",
"    Fibrin glue application is another technique that has been used in small series to successfully close fistulae after bariatric surgery, either alone or in conjunction with other techniques such as hemoclipping, suturing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/37,44-46\">",
"     37,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, there are a few case series describing the successful endoscopic closure of gastrocutaneous fistulae with a novel biomaterial derived from porcine small intestine that stimulates fibroblast proliferation and serves as a scaffold for host cells to replace or repair damaged tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Commercially available as sheets that can be cut into small strips or as a preformed cone-shaped plug, this biomaterial (Surgisis&reg;, Cook Medical Inc, Bloomington, IN) can be packed into the fistula under endoscopic guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Band erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intragastric band erosion is a potential complication of LAGB, VBG, and vertical banded gastric bypass (a modification of gastric bypass in which a silastic ring is placed around the pouch to reinforce the stoma). Although uncommon, band erosion should be suspected in patients who regain weight after VBG or LAGB. Band erosion can also result in abdominal pain, vomiting, gastrointestinal bleeding, intra-abdominal abscess, or fistula formation. In many cases, the first sign of band erosion is infection (cellulitis) at the site of the subcutaneous access port [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H52#H52\">",
"     \"Complications of bariatric surgery\", section on 'Erosion of mesh band'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H43#H43\">",
"     \"Complications of bariatric surgery\", section on 'Band erosion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic treatment for band erosion is the surgical removal of the eroded band, with or without a revisional bariatric operation. However, surgical therapy can be very complicated secondary to a significant inflammatory reaction involving the proximal stomach and left lobe of the liver. Successful endoscopic management of this complication has been described with a variety of techniques designed to transect the eroded band, including the use of Nd:YAG laser, endoscopic scissors, and band cutters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Most authors suggest endoscopic removal only if the buckle of the band is visible endoscopically (ie, it is eroded through the gastric wall).",
"   </p>",
"   <p>",
"    A two-step technique has been described utilizing temporary self-expanding plastic stent placement to promote full intragastric migration of the band (by causing pressure-induced necrosis between the band and gastric wall), followed by band transection and extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/55\">",
"     55",
"    </a>",
"    ]. Band transection is accomplished under endoscopic control by threading and gripping the band with a guidewire that is progressively tightened to cut the band.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Unraveled suture material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unraveled nonabsorbable suture material within the lumen of the gastrojejunal anastomosis following RYGB (",
"    <a class=\"graphic graphic_picture graphicRef76160 \" href=\"UTD.htm?36/42/37536\">",
"     picture 6",
"    </a>",
"    ) can result in pain, marginal ulcers, and obstructive symptoms (secondary to food",
"    <span class=\"nowrap\">",
"     entrapment/bezoar",
"    </span>",
"    formation) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,56\">",
"     6,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Endoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of unraveled nonabsorbable suture material is only required in patients who are symptomatic. Removal can be accomplished by cutting the suture material with endoscopic scissors and then extracting it with biopsy or rat-toothed forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/6,56,57\">",
"     6,56,57",
"    </a>",
"    ]. Although the clinical relevance of suture erosion is not always clear, one case series reported symptom resolution or improvement in over 80 percent of patients after removal of the eroded sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Esophageal dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Megaesophagus or pseudoachalasia syndrome has been reported as a potential complication of LAGB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. This complication is not managed endoscopically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H47#H47\">",
"     \"Complications of bariatric surgery\", section on 'Esophageal dilatation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Marginal ulcers and acute gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal (GI) bleeding occurs in approximately 1 to 4 percent of patients after Roux-en-Y gastric bypass (RYGB) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. Early postoperative hemorrhage, typically defined as GI bleeding occurring within 48 hours after surgery, usually arises from the staple lines (gastric pouch, gastric remnant) or anastomoses (gastrojejunostomy, jejunojejunostomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/62\">",
"     62",
"    </a>",
"    ]. Marginal ulcers should be considered in patients who present with bleeding after the early postoperative period.",
"   </p>",
"   <p>",
"    Marginal ulcers occur at an anastomosis and, in the case of an RYGB, are typically located on the jejunal side of the gastrojejunal anastomosis (",
"    <a class=\"graphic graphic_picture graphicRef66371 \" href=\"UTD.htm?19/0/19458\">",
"     picture 7",
"    </a>",
"    ). They may be associated with stomal stenosis or occur at sites where suture material is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H30#H30\">",
"     \"Complications of bariatric surgery\", section on 'Marginal ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Marginal ulcers typically occur early in the postoperative course. A study of 441 patients who underwent routine endoscopy (ie, regardless of symptoms) following RYGB at one month and again after a mean of 17 months found that the majority of marginal ulcers developed within the first four weeks of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/66\">",
"     66",
"    </a>",
"    ]. Early marginal ulcers occurred in 4 to 12 percent (depending upon the type of operation), while late marginal ulcers occurred in less than 1 percent.",
"   </p>",
"   <p>",
"    Cigarette smoking is a significant risk factor for marginal ulcers after RYGB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/7,67,68\">",
"     7,67,68",
"    </a>",
"    ]. Other risk factors that have been identified include Helicobacter pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/7,69-71\">",
"     7,69-71",
"    </a>",
"    ] and nonsteroidal antiinflammatory drugs (NSAID) use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/7\">",
"     7",
"    </a>",
"    ], while the use of proton pump inhibitors appears to be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Endoscopic management of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic management of acute GI bleeding in the early postoperative period can be challenging because of the risk of disrupting the still-immature staple lines and anastomoses, as well as the relative inaccessibility of the jejunojejunostomy and bypassed stomach. Thus, therapeutic endoscopy should be reserved for patients who manifest significant hemorrhage and fail to respond to supportive therapy. For patients who require endoscopy, it may be prudent to perform the procedure in the operating room with the patient under general anesthesia with endotracheal intubation. This approach reduces the risk of aspiration and permits immediate operative intervention should endoscopic therapy fail [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful endoscopic therapy of early postoperative bleeding arising from the gastric pouch, gastrojejunostomy, or jejunojejunostomy has been described in case reports and series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/64,72-75\">",
"     64,72-75",
"    </a>",
"    ]. Standard hemostatic modalities, such as epinephrine injection, thermal therapy, and mechanical ligation with hemoclips, can be safely used in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Endoscopic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest study included 30 patients with intraoperative, immediate (within four hours of surgery), or early postoperative upper GI bleeding after laparoscopic RYGB, 27 of whom underwent endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/64\">",
"     64",
"    </a>",
"    ]. Endoscopic intervention was performed in 23 patients (85 percent) using epinephrine injection, heater probe, hemoclips, or a combination of these modalities. Rebleeding rates were high, with 16 patients (59 percent) experiencing a second episode of bleeding (five of whom required repeat endoscopy), and three patients experiencing a third episode. No patients required reoperation, and there were two procedure-related complications (aspiration and perforation at the gastrojejunostomy).",
"   </p>",
"   <p>",
"    Patients with bleeding related to a marginal ulcer are treated like other patients with peptic ulcer bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Choledocholithiasis and other biliary tract complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid weight loss is a risk factor for gallstones. However, endoscopic retrograde cholangiopancreatography (ERCP) after RYGB presents a significant technical challenge because the major papilla is not readily accessible via the peroral approach using standard ERCP equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28489/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"     \"ERCP in patients with Roux-en-Y anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complications of bariatric surgery can be managed endoscopically, reducing or even eliminating the need for high-risk reoperation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with evidence of gastrointestinal (GI) bleeding or biliary obstruction, or whose symptoms persist despite counseling and behavior modification, an evaluation with endoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic imaging is warranted to identify a source and exclude structural complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal endoscopic findings following bariatric surgery include stomal stenoses, stomal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pouch dilation, staple line dehiscences, gastrogastric fistulae, band erosion, unraveled suture material, esophageal dilation, and marginal ulcers. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Abnormal endoscopic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic endoscopy is frequently used to manage acute GI bleeding and stomal stenoses following bariatric surgery. Novel endoscopic techniques are also employed to treat stoma and pouch dilation, fistulae, band erosion, and biliary complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Abnormal endoscopic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic dilation, preferably with through-the-scope balloon dilators, is safe and effective therapy for stomal stenosis or an anastomotic stricture. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stomal stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emerging endoscopic techniques (such as endoscopic",
"      <span class=\"nowrap\">",
"       suturing/tissue",
"      </span>",
"      plication devices) and novel implementation of existing technology (stents, fibrin glue) may offer less invasive approaches to the management of anastomotic leaks, fistulae, staple line dehiscences, and stomal and pouch dilation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Fistulae and leaks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Stomal and/or pouch dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute gastrointestinal bleeding after bariatric surgery can be treated with standard endoscopic hemostasis modalities, including injection therapy, electrocoagulation, and hemoclipping. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Marginal ulcers and acute gastrointestinal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary challenge in performing endoscopic retrograde cholangiopancreatography (ERCP) after RYGB is accessing the region of the major papilla. Various techniques are being devised to address this problem (",
"      <a class=\"graphic graphic_table graphicRef54031 \" href=\"UTD.htm?2/41/2717\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"       \"ERCP in patients with Roux-en-Y anatomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/1\">",
"      ASGE STANDARDS OF PRACTICE COMMITTEE, Anderson MA, Gan SI, et al. Role of endoscopy in the bariatric surgery patient. Gastrointest Endosc 2008; 68:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/2\">",
"      Obstein KL, Thompson CC. Endoscopy after bariatric surgery (with videos). Gastrointest Endosc 2009; 70:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/3\">",
"      Huang CS. The role of the endoscopist in a multidisciplinary obesity center. Gastrointest Endosc 2009; 70:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/4\">",
"      Huang CS, Forse RA, Jacobson BC, Farraye FA. Endoscopic findings and their clinical correlations in patients with symptoms after gastric bypass surgery. Gastrointest Endosc 2003; 58:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/5\">",
"      Yang CS, Lee WJ, Wang HH, et al. Spectrum of endoscopic findings and therapy in patients with upper gastrointestinal symptoms after laparoscopic bariatric surgery. Obes Surg 2006; 16:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/6\">",
"      Lee JK, Van Dam J, Morton JM, et al. Endoscopy is accurate, safe, and effective in the assessment and management of complications following gastric bypass surgery. Am J Gastroenterol 2009; 104:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/7\">",
"      Wilson JA, Romagnuolo J, Byrne TK, et al. Predictors of endoscopic findings after Roux-en-Y gastric bypass. Am J Gastroenterol 2006; 101:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/8\">",
"      Sanyal AJ, Sugerman HJ, Kellum JM, et al. Stomal complications of gastric bypass: incidence and outcome of therapy. Am J Gastroenterol 1992; 87:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/9\">",
"      Feitoza AB, Baron TH. Endoscopy and ERCP in the setting of previous upper GI tract surgery. Part I: reconstruction without alteration of pancreaticobiliary anatomy. Gastrointest Endosc 2001; 54:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/10\">",
"      Stellato TA, Crouse C, Hallowell PT. Bariatric surgery: Creating new challenges for the endoscopist. Gastrointest Endosc 2003; 57:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/11\">",
"      Flickinger EG, Sinar DR, Pories WJ, et al. The bypassed stomach. Am J Surg 1985; 149:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/12\">",
"      Sinar DR, Flickinger EG, Park HK, Sloss RR. Retrograde endoscopy of the bypassed stomach segment after gastric bypass surgery: unexpected lesions. South Med J 1985; 78:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/13\">",
"      Pai RD, Carr-Locke DL, Thompson CC. Endoscopic evaluation of the defunctionalized stomach by using ShapeLock technology (with video). Gastrointest Endosc 2007; 66:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/14\">",
"      Moreels TG, Hubens GJ, Ysebaert DK, et al. Diagnostic and therapeutic double-balloon enteroscopy after small bowel Roux-en-Y reconstructive surgery. Digestion 2009; 80:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/15\">",
"      Tagaya N, Kasama K, Inamine S, et al. Evaluation of the excluded stomach by double-balloon endoscopy after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2007; 17:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/16\">",
"      Kuga R, Safatle-Ribeiro AV, Faintuch J, et al. Endoscopic findings in the excluded stomach after Roux-en-Y gastric bypass surgery. Arch Surg 2007; 142:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/17\">",
"      Safatle-Ribeiro AV, Kuga R, Iriya K, et al. What to expect in the excluded stomach mucosa after vertical banded Roux-en-Y gastric bypass for morbid obesity. J Gastrointest Surg 2007; 11:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/18\">",
"      Peifer KJ, Shiels AJ, Azar R, et al. Successful endoscopic management of gastrojejunal anastomotic strictures after Roux-en-Y gastric bypass. Gastrointest Endosc 2007; 66:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/19\">",
"      Barba CA, Butensky MS, Lorenzo M, Newman R. Endoscopic dilation of gastroesophageal anastomosis stricture after gastric bypass. Surg Endosc 2003; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/20\">",
"      Ahmad J, Martin J, Ikramuddin S, et al. Endoscopic balloon dilation of gastroenteric anastomotic stricture after laparoscopic gastric bypass. Endoscopy 2003; 35:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/21\">",
"      Csendes A, Burgos AM, Burdiles P. Incidence of anastomotic strictures after gastric bypass: a prospective consecutive routine endoscopic study 1 month and 17 months after surgery in 441 patients with morbid obesity. Obes Surg 2009; 19:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/22\">",
"      Ryskina KL, Miller KM, Aisenberg J, et al. Routine management of stricture after gastric bypass and predictors of subsequent weight loss. Surg Endosc 2010; 24:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/23\">",
"      Ukleja A, Afonso BB, Pimentel R, et al. Outcome of endoscopic balloon dilation of strictures after laparoscopic gastric bypass. Surg Endosc 2008; 22:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/24\">",
"      Catalano MF, Chua TY, Rudic G. Endoscopic balloon dilation of stomal stenosis following gastric bypass. Obes Surg 2007; 17:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/25\">",
"      Go MR, Muscarella P 2nd, Needleman BJ, et al. Endoscopic management of stomal stenosis after Roux-en-Y gastric bypass. Surg Endosc 2004; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/26\">",
"      Tulman AB, Boyce HW Jr. Complications of esophageal dilation and guidelines for their prevention. Gastrointest Endosc 1981; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/27\">",
"      Eubanks S, Edwards CA, Fearing NM, et al. Use of endoscopic stents to treat anastomotic complications after bariatric surgery. J Am Coll Surg 2008; 206:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/28\">",
"      Morton JM. Weight gain after bariatric surgery as a result of large gastric stoma: endotherapy with sodium morrhuate to induce stomal stenosis may prevent the need for surgical revision. Gastrointest Endosc 2007; 66:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/29\">",
"      Knol JA. Management of the problem patient after bariatric surgery. Gastroenterol Clin North Am 1994; 23:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/30\">",
"      Catalano MF, Rudic G, Anderson AJ, Chua TY. Weight gain after bariatric surgery as a result of a large gastric stoma: endotherapy with sodium morrhuate may prevent the need for surgical revision. Gastrointest Endosc 2007; 66:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/31\">",
"      Schweitzer M. Endoscopic intraluminal suture plication of the gastric pouch and stoma in postoperative Roux-en-Y gastric bypass patients. J Laparoendosc Adv Surg Tech A 2004; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/32\">",
"      Thompson CC, Slattery J, Bundga ME, Lautz DB. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-Y gastric bypass: a possible new option for patients with weight regain. Surg Endosc 2006; 20:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/33\">",
"      Mullady DK, Lautz DB, Thompson CC. Treatment of weight regain after gastric bypass surgery when using a new endoscopic platform: initial experience and early outcomes (with video). Gastrointest Endosc 2009; 70:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/34\">",
"      Fern&aacute;ndez-Esparrach G, Lautz DB, Thompson CC. Peroral endoscopic anastomotic reduction improves intractable dumping syndrome in Roux-en-Y gastric bypass patients. Surg Obes Relat Dis 2010; 6:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/35\">",
"      Thompson CC, Carr-Locke DL, Saltzman J, et al. Peroral endoscopic repair of staple-line dehiscence in Roux-en-Y gastric bypass: a less invasive approach [abstract]. Gastroenterology 2004; 126 (Suppl 2):A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/36\">",
"      Fernandez-Esparrach G, Lautz DB, Thompson CC. Endoscopic repair of gastrogastric fistula after Roux-en-Y gastric bypass: a less-invasive approach. Surg Obes Relat Dis 2010; 6:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/37\">",
"      Merrifield BF, Lautz D, Thompson CC. Endoscopic repair of gastric leaks after Roux-en-Y gastric bypass: a less invasive approach. Gastrointest Endosc 2006; 63:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/38\">",
"      Spaun GO, Martinec DV, Kennedy TJ, Swanstr&ouml;m LL. Endoscopic closure of gastrogastric fistulas by using a tissue apposition system (with videos). Gastrointest Endosc 2010; 71:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/39\">",
"      Eisendrath P, Cremer M, Himpens J, et al. Endotherapy including temporary stenting of fistulas of the upper gastrointestinal tract after laparoscopic bariatric surgery. Endoscopy 2007; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/40\">",
"      Fukumoto R, Orlina J, McGinty J, Teixeira J. Use of Polyflex stents in treatment of acute esophageal and gastric leaks after bariatric surgery. Surg Obes Relat Dis 2007; 3:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/41\">",
"      Edwards CA, Bui TP, Astudillo JA, et al. Management of anastomotic leaks after Roux-en-Y bypass using self-expanding polyester stents. Surg Obes Relat Dis 2008; 4:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/42\">",
"      Blackmon SH, Santora R, Schwarz P, et al. Utility of removable esophageal covered self-expanding metal stents for leak and fistula management. Ann Thorac Surg 2010; 89:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/43\">",
"      Serra C, Baltasar A, Andreo L, et al. Treatment of gastric leaks with coated self-expanding stents after sleeve gastrectomy. Obes Surg 2007; 17:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/44\">",
"      Papavramidis ST, Eleftheriadis EE, Papavramidis TS, et al. Endoscopic management of gastrocutaneous fistula after bariatric surgery by using a fibrin sealant. Gastrointest Endosc 2004; 59:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/45\">",
"      Papavramidis ST, Eleftheriadis EE, Apostolidis DN, Kotzampassi KE. Endoscopic fibrin sealing of high-output non-healing gastrocutaneous fistulas after vertical gastroplasty in morbidly obese patients. Obes Surg 2001; 11:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/46\">",
"      Papavramidis TS, Kotzampassi K, Kotidis E, et al. Endoscopic fibrin sealing of gastrocutaneous fistulas after sleeve gastrectomy and biliopancreatic diversion with duodenal switch. J Gastroenterol Hepatol 2008; 23:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/47\">",
"      Maluf-Filho F, Hondo F, Halwan B, et al. Endoscopic treatment of Roux-en-Y gastric bypass-related gastrocutaneous fistulas using a novel biomaterial. Surg Endosc 2009; 23:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/48\">",
"      Toussaint E, Eisendrath P, Kwan V, et al. Endoscopic treatment of postoperative enterocutaneous fistulas after bariatric surgery with the use of a fistula plug: report of five cases. Endoscopy 2009; 41:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/49\">",
"      Abu-Abeid S, Keidar A, Gavert N, et al. The clinical spectrum of band erosion following laparoscopic adjustable silicone gastric banding for morbid obesity. Surg Endosc 2003; 17:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/50\">",
"      Fobi M, Lee H, Igwe D, et al. Band erosion: incidence, etiology, management and outcome after banded vertical gastric bypass. Obes Surg 2001; 11:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/51\">",
"      Karmali S, Snyder B, Wilson EB, et al. Endoscopic management of eroded prosthesis in vertical banded gastroplasty patients. Surg Endosc 2010; 24:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/52\">",
"      Lattuada E, Zappa MA, Mozzi E, et al. Band erosion following gastric banding: how to treat it. Obes Surg 2007; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/53\">",
"      Lunde OC. Endoscopic laser therapy for band penetration of the gastric wall after gastric banding for morbid obesity. Endoscopy 1991; 23:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/54\">",
"      Weiss H, Nehoda H, Labeck B, et al. Gastroscopic band removal after intragastric migration of adjustable gastric band: a new minimal invasive technique. Obes Surg 2000; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/55\">",
"      Blero D, Eisendrath P, Vandermeeren A, et al. Endoscopic removal of dysfunctioning bands or rings after restrictive bariatric procedures. Gastrointest Endosc 2010; 71:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/56\">",
"      Yu S, Jastrow K, Clapp B, et al. Foreign material erosion after laparoscopic Roux-en-Y gastric bypass: findings and treatment. Surg Endosc 2007; 21:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/57\">",
"      Frezza EE, Herbert H, Ford R, Wachtel MS. Endoscopic suture removal at gastrojejunal anastomosis after Roux-en-Y gastric bypass to prevent marginal ulceration. Surg Obes Relat Dis 2007; 3:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/58\">",
"      Dargent J. Esophageal dilatation after laparoscopic adjustable gastric banding: definition and strategy. Obes Surg 2005; 15:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/59\">",
"      Arias IE, Radulescu M, Stiegeler R, et al. Diagnosis and treatment of megaesophagus after adjustable gastric banding for morbid obesity. Surg Obes Relat Dis 2009; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/60\">",
"      Wiesner W, Hauser M, Sch&ouml;b O, et al. Pseudo-achalasia following laparoscopically placed adjustable gastric banding. Obes Surg 2001; 11:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/61\">",
"      Braley SC, Nguyen NT, Wolfe BM. Late gastrointestinal hemorrhage after gastric bypass. Obes Surg 2002; 12:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/62\">",
"      Nguyen NT, Rivers R, Wolfe BM. Early gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg 2003; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/63\">",
"      Nguyen NT, Longoria M, Chalifoux S, Wilson SE. Gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg 2004; 14:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/64\">",
"      Jamil LH, Krause KR, Chengelis DL, et al. Endoscopic management of early upper gastrointestinal hemorrhage following laparoscopic Roux-en-Y gastric bypass. Am J Gastroenterol 2008; 103:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/65\">",
"      Bakhos C, Alkhoury F, Kyriakides T, et al. Early postoperative hemorrhage after open and laparoscopic roux-en-y gastric bypass. Obes Surg 2009; 19:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/66\">",
"      Csendes A, Burgos AM, Altuve J, Bonacic S. Incidence of marginal ulcer 1 month and 1 to 2 years after gastric bypass: a prospective consecutive endoscopic evaluation of 442 patients with morbid obesity. Obes Surg 2009; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/67\">",
"      Schreiber H, Ben-Meir A, Sonpal I, et al. Cigarette smoking, but not the presence of H. pylori, is associated with anastomotic ulcers in Roux-en-Y gastric bypass patients. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery 2005; 1:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/68\">",
"      Ben-Meir A, Sonpal I, Patterson L, et al. Cigarette smoking, but not NSAID or alcohol use or comorbidities, is associated with anastomotic ulcers in Roux-en-Y Gastric Bypass (RYGB) patients. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery 2005; 1:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/69\">",
"      Renshaw AA, Rabaza JR, Gonzalez AM, Verdeja JC. Helicobacter pylori infection in patients undergoing gastric bypass surgery for morbid obesity. Obes Surg 2001; 11:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/70\">",
"      Schirmer B, Erenoglu C, Miller A. Flexible endoscopy in the management of patients undergoing Roux-en-Y gastric bypass. Obes Surg 2002; 12:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/71\">",
"      Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc 2007; 21:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/72\">",
"      Moretto M, Mottin CC, Padoin AV, et al. Endoscopic management of bleeding after gastric bypass -- a therapeutic alternative. Obes Surg 2004; 14:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/73\">",
"      Fern&aacute;ndez-Esparrach G, Bordas JM, Pellis&eacute; M, et al. Endoscopic management of early GI hemorrhage after laparoscopic gastric bypass. Gastrointest Endosc 2008; 67:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/74\">",
"      Steffen R. Early gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg 2003; 13:466; author reply 466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/75\">",
"      Tang SJ, Rivas H, Tang L, et al. Endoscopic hemostasis using endoclip in early gastrointestinal hemorrhage after gastric bypass surgery. Obes Surg 2007; 17:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28489/abstract/76\">",
"      Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. Gastroenterol Clin North Am 2010; 39:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2655 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28489=[""].join("\n");
var outline_f27_52_28489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREPARATION FOR ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXPECTED FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Roux-en-Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vertical banded gastroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laparoscopic adjustable gastric banding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ABNORMAL ENDOSCOPIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Predictors of abnormal findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Time since surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stomal stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Endoscopic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stomal and/or pouch dilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Endoscopic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fistulae and leaks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Endoscopic closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Band erosion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Unraveled suture material",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Endoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Esophageal dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Marginal ulcers and acute gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Endoscopic management of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Choledocholithiasis and other biliary tract complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2655|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/35/33329\" title=\"figure 1\">",
"      Roux en Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/28/36303\" title=\"figure 2\">",
"      Vertical band gastroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/54/22368\" title=\"figure 3\">",
"      Adjustable gastric band",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/40/36480\" title=\"figure 4\">",
"      Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/33/19987\" title=\"figure 5\">",
"      Duodenal switch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2655|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/53/6992\" title=\"picture 1\">",
"      Anastomosis after bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/21/16721\" title=\"picture 2\">",
"      Banded gastroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28865\" title=\"picture 3\">",
"      Gastric cardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/39/17008\" title=\"picture 4\">",
"      Stenosis after bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/3/43057\" title=\"picture 5\">",
"      Staple line dehiscence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/42/37536\" title=\"picture 6\">",
"      Unraveled suture material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/0/19458\" title=\"picture 7\">",
"      Ulcer after gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2655|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/41/2717\" title=\"table 1\">",
"      Approaches for ERCP in patients with Roux-en-Y anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=related_link\">",
"      ERCP in patients with Roux-en-Y anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=related_link\">",
"      Imaging studies after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28490="Overview of comprehensive patient assessment in palliative care";
var content_f27_52_28490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of comprehensive patient assessment in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Tomasz R Okon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Robert M Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/52/28490/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/52/28490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11672006\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients who are facing a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Palliative care may be provided along with curative or life-prolonging treatments (",
"    <a class=\"graphic graphic_algorithm graphicRef64252 \" href=\"UTD.htm?42/14/43246\">",
"     algorithm 1",
"    </a>",
"    ). It also extends to the family&rsquo;s bereavement period. &nbsp;",
"   </p>",
"   <p>",
"    In addition to symptom management, other principal objectives of comprehensive palliative support include establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family caregivers; and coordination across sites of care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link&amp;anchor=H549034653#H549034653\">",
"     \"Palliative care: Benefits, services, and models of care\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the scope of palliative care, a unique approach to clinical evaluation is required. Although a comprehensive palliative assessment includes all the standard elements of a medical history and relevant aspects of the physical examination, it also extends beyond the traditional domains.",
"   </p>",
"   <p>",
"    An overview of comprehensive patient assessment in palliative care is presented here, including the concept of &ldquo;total pain&rdquo; and its clinical ramifications, the adequacy of assessment of palliative care needs in this population, and the components of the comprehensive palliative assessment. Assessment methods designed primarily for care of actively dying patients (eg, Liverpool Care Pathway) or for research and quality improvement in palliative care are not discussed here; a more detailed review of the approach to symptom assessment in palliative care patients, a general discussion of the benefits of palliative care, and the philosophy and utilization of hospice care for patients with terminal illness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672013\">",
"    <span class=\"h1\">",
"     SOURCES AND CLINICAL MANIFESTATIONS OF SUFFERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perception of discomfort and burden of illness among palliative care patients is highly individualized. To address the heterogeneity that is inherent in suffering, Dame Cicely Saunders, the foundress of modern hospice and palliative care, introduced the term \"total pain.\" Recalling one of her patient&rsquo;s testimonies, &ldquo;&hellip;The pain began in my back, but now it seems that all of me is wrong. My husband and my son were marvelous but they were at work and they would have to stay off and lose their money. Everything seemed against me and nobody seemed to understand&hellip;&rdquo; Dr. Saunders observed that her patient&rsquo;s pain included not only physical but also &ldquo;&hellip;emotional and mental suffering, her social problems, and her spiritual need for security and meaning&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/2\">",
"     2",
"    </a>",
"    ]. Accordingly, the concept of &ldquo;total pain&rdquo;, which provides a defining framework for patient assessment in palliative care, refers to the complex mechanisms and manifestations of suffering, including its physical, emotional, socioeconomic, and spiritual components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672020\">",
"    <span class=\"h2\">",
"     Diversity of individual experience of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person's pain or malaise, their body image, the meaning of their illness, their desires, relationships, and values or spiritual beliefs all contribute to their experience of illness and suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/3\">",
"     3",
"    </a>",
"    ]. However, a precise clinical taxonomy of suffering is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/4\">",
"     4",
"    </a>",
"    ] because total pain is constructed in a highly individual, sometimes idiosyncratic way. There is no single good way of facing a serious illness; likewise, there is no single &ldquo;good&rdquo; death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the diversity of the individual experience of suffering, the specific palliative needs and goals of individual patients are challenging to identify a priori, or derive from population-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/6\">",
"     6",
"    </a>",
"    ]. Yet, there has been a tendency among clinicians and legislators to predefine the desirable attributes of effective palliative care. As an example, the design of the United States Medicare hospice benefit, seeking cost-neutrality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/7\">",
"     7",
"    </a>",
"    ], pre-selects patients for home care, and requires a focus on comfort measures rather than access to all available treatments. While a preference for home-based comfort measures may be common, it is not universal. In one study, only 35 percent of seriously-ill patients wanted to die at home [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/5\">",
"     5",
"    </a>",
"    ]. Similarly, as many as 48 percent of patients in this study cohort (versus only 5 to 7 percent of health care providers) considered access to all available treatments an important aspect of palliative care at the end of life, regardless of the chance of recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link&amp;anchor=H691082#H691082\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\", section on 'The US Medicare hospice benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rank importance of common symptoms and care needs also differs between patients who have an advanced, life threatening disease such as cancer and their caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/8\">",
"     8",
"    </a>",
"    ]. In one study, patients with inoperable lung cancer self-reported a number of distressing problems that were not included in comprehensive symptom questionnaires that were available for research or clinical care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/9\">",
"     9",
"    </a>",
"    ]. In another, patients differed substantially from their physicians with regard to factors and priorities that impacted treatment decisions for their malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies report that even the presence of a symptom as seemingly universally undesirable as pain is subject to individual interpretation and varying treatment preferences. One group found that only 29 percent of terminally-ill patients who reported pain desired additional analgesic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the diversity of individual suffering, it is not surprising that a 2010 review of guidelines and policies from the US, UK, Canada, and Australia found few uniform sets of fixed patient expectations and clinical standards for palliative care. They concluded that &ldquo;palliative care staff have to continuously adapt their model of caring to the specific needs and values of each patient&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672027\">",
"    <span class=\"h2\">",
"     Interpersonal sources of suffering",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to individual sources of suffering, palliative care patients face anticipatory grief, which often leads them to relate to their families, communities, and professional caregivers with strong emotions. While these relationships are commonly supportive and adaptive, the distress felt by each of these parties (patient, family, and physician) may negatively impact the others. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the case of impending disease progression despite treatment, a patient&rsquo;s unquestioning trust in his or her physician may be inadvertently associated with the emergence of grief and self-doubt on the part of the doctor. That emotion, in turn, may impact the patient and family.",
"     </li>",
"     <li>",
"      In one study, oncologists reported altered treatment decisions, mental distraction, as well as distancing or withdrawal from both the patients and their families as the patient got closer to death [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, a stronger doctor&shy;patient relationship was associated with lower prognostic accuracy on the part of the physician, which could potentially alter a treatment plan [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings illustrate the need for comprehensive evaluation of not only the patient but also",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family and caregivers, as well as close introspection on the part of the physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734218\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF PALLIATIVE CARE NEEDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672034\">",
"    <span class=\"h2\">",
"     Gaps in general medical assessment&nbsp;in palliative care patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional methods of clinical assessment (ie, the interview, physical examination, and diagnostic work-up), and care planning frequently miss many target symptoms for palliative care management, particularly in diseases other than cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Patients who have an advanced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness are frequently reluctant to discuss specific issues related to prognosis, or advance care planning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/17\">",
"     17",
"    </a>",
"    ], while on the other hand, physicians who lack a comprehensive, structured assessment approach risk underdiagnosing suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/8\">",
"     8",
"    </a>",
"    ] and failing to discern actual patient needs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/16\">",
"     16",
"    </a>",
"    ] or preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discordance between patient-reported and physician-documented symptoms was shown in a study which compared 58 questionnaires completed by patients with advanced cancer and their paired physician-completed medical records [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/19\">",
"     19",
"    </a>",
"    ]. There was good concordance for pain (96 percent), but patients reported most other symptoms or problems more often than did their doctors (concordance rate 2 to 52 percent).",
"   </p>",
"   <p>",
"    Others have shown poor concordance between physician&rsquo;s and patient&rsquo;s agreement on the diagnosis, and on whether or not end-of-life care options were discussed in patients with terminal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/20\">",
"     20",
"    </a>",
"    ]. In one report, oncologists caring for patients with metastatic cancer, whose subsequent median survival was six to seven months, discussed &ldquo;wishes about the care they would want to receive if they were dying&rdquo; with only 39 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/21\">",
"     21",
"    </a>",
"    ]. The lack of structured discussion of prognosis or assessment of what the patient knows may lead to misunderstandings. Indeed, one study found that a majority of patients with incurable stage IV colon and lung cancer mistakenly believed that their malignancies were curable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14432240\">",
"     'Ramifications of accurate illness understanding'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collectively, these findings suggest that individual sources of suffering, preferences, and palliative care plans for specific patients can be formulated only through comprehensive and uniquely structured palliative assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/12\">",
"     12",
"    </a>",
"    ], which differs from traditional medical evaluation. Some data suggest that such a comprehensive approach improves the documentation of patient needs, but whether outcomes are improved remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734093\">",
"    <span class=\"h2\">",
"     Unique aspects of palliative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard approach to clinical palliative care assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/12\">",
"     12",
"    </a>",
"    ]. In general, while including the traditional components of medical evaluation (medical and psychosocial history, physical examination), comprehensive palliative assessment involves unique content, focus, and sources of information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Content &ndash;",
"      </strong>",
"      Comprehensive palliative assessment includes six unique domains examined in a structured manner: pain and other physical symptoms; psychological, psychiatric, and cognitive symptoms; illness understanding and care preferences (ie, personal goals, expectations, understanding of illness trajectory and risks versus benefits of therapies); existential and spiritual concerns; social and economic resources and needs of patients and caregivers, including for care in the home; and continuity of and coordination of care across settings [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Focus",
"      </strong>",
"      &ndash; The unit of care in palliative care consists of both the patient and his or her family. The needs of both must be examined in the course of comprehensive palliative assessment. In addition, the patient&rsquo;s own, frequently competing and evolving care preferences and goals, rather than solely pathophysiologic and clinical data, define the focus and organization of the assessment.",
"     </li>",
"     <li>",
"      <strong>",
"       Sources",
"      </strong>",
"      and",
"      <strong>",
"       process",
"      </strong>",
"      <strong>",
"       for treatment planning",
"      </strong>",
"      &ndash; Rather than gathering information exclusively from the patient (or caregivers) and medical records, palliative evaluation utilizes a broad range of sources, each contributing to the final assessment. In an interdisciplinary manner, the physician leads nursing staff, chaplains, social workers, therapists, and nutritionists to perform discipline-specific evaluative tasks, together forming the comprehensive palliative assessment. Tasks that are best delegated to expert non-physician team members may include evaluation of existential and spiritual domains, or economic needs, and care coordination; however, specific distribution will vary depending on local expertise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The palliative assessment must be grounded in an attitude of openness towards the other person, and being present to the other's suffering. When this occurs, the diagnostic evaluation itself becomes a part of the therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/25\">",
"     25",
"    </a>",
"    ]. This concept is embodied in the words of the Boston physician, Alfred Worcester, remarking on the care of the aged and the dying, who said &ldquo;In the practice of our art it often matters little what medicine is given, but matters much that we give ourselves with our pills&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Good communication skills are necessary. While assessing symptoms and burdens in a focused manner, we recommend incorporating open-ended questions and, after questions are asked, actively listening to the answers. This process is aided by using empathic comments [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/27\">",
"     27",
"    </a>",
"    ], reframing, speaking in the patient's own language and level of understanding, and exploring both the cognitive and emotional meanings of the response. Acknowledging and legitimizing the individual's values and concerns communicates respect, leads to an enhanced sense of dignity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/28\">",
"     28",
"    </a>",
"    ], and may reduce rates of anxiety and depression in the relatives of patients who are dying in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A comprehensive palliative assessment is rarely completed in one session, and frequently extends over multiple encounters due to complexity of clinical content and time required to develop necessary rapport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672759\">",
"    <span class=\"h2\">",
"     Identifying patients who need a palliative care assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 consensus statement from the US Center to Advance Palliative Care proposed criteria for identifying patients in need of general palliative assessment at the time of hospital admission (",
"    <a class=\"graphic graphic_table graphicRef76969 \" href=\"UTD.htm?30/62/31724\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients meeting these criteria should be evaluated by their principal hospital physicians (or other members of the primary treatment team) to address some of the basic domains of palliative care (",
"    <a class=\"graphic graphic_table graphicRef51669 \" href=\"UTD.htm?36/16/37131\">",
"     table 2",
"    </a>",
"    ). A subsequent referral for consultation and comprehensive assessment by a palliative medicine specialist should be obtained for problems that challenge the capabilities of the primary team. Highly burdensome or refractory symptoms in a patient with an advanced serious or life-threatening illness (particularly pain, depression, anxiety, confusion, fatigue, breathlessness, insomnia, nausea, constipation, diarrhea, or anorexia) should prompt palliative care consultation. (See",
"    <a class=\"local\" href=\"#H9239028\">",
"     'Physical symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Analogous, detailed criteria for palliative care assessment and specialist referral are available for cancer patients, including those being cared for in the outpatient setting, from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef87162 \" href=\"UTD.htm?24/46/25324\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672056\">",
"    <span class=\"h1\">",
"     DOMAINS OF PALLIATIVE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive palliative assessment is rarely completed in one session, and frequently extends over multiple encounters due to complexity of clinical content and time required to develop necessary rapport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9239028\">",
"    <span class=\"h2\">",
"     Physical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies focused on cancer, AIDS, heart disease, chronic obstructive pulmonary disease, and chronic kidney disease identified 11 of the most prevalent symptoms in patients with end-stage illness: pain, depression, anxiety, confusion, fatigue, breathlessness, insomnia, nausea, constipation, diarrhea, and anorexia (",
"    <a class=\"graphic graphic_table graphicRef87163 \" href=\"UTD.htm?11/27/11710\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/31\">",
"     31",
"    </a>",
"    ]. A mnemonic PAIN RULES (",
"    <a class=\"graphic graphic_table graphicRef74629 \" href=\"UTD.htm?33/8/33931\">",
"     table 5",
"    </a>",
"    ),",
"    <strong>",
"     &nbsp;",
"    </strong>",
"    derived from prevalence studies, is one convenient way to recall and target the critical symptom categories that must be addressed.",
"   </p>",
"   <p>",
"    Each identified symptom should be further investigated in regard to its Onset, Palliating and Provoking factors, Quality, Response to previous treatments, Related",
"    <span class=\"nowrap\">",
"     factors/symptoms,",
"    </span>",
"    Severity and Temporality, as well as the Meaning of the",
"    <span class=\"nowrap\">",
"     symptom/burden",
"    </span>",
"    to the patient (MOPQRST history structure which is the traditional OPQRST history structure for defining a chief complaint plus M for the Meaning of the symptom burden) (",
"    <a class=\"graphic graphic_table graphicRef87818 \" href=\"UTD.htm?12/59/13243\">",
"     table 6",
"    </a>",
"    ). When consistent with patient&rsquo;s preferences, the etiology of the symptom(s) should be established in order to best palliate treatable conditions. A detailed pain history must be obtained to identify and treat discrete pain syndromes when present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30666?source=see_link\">",
"     \"Assessment and management of dyspnea in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6922?source=see_link\">",
"     \"Palliative care: Overview of fatigue, weakness, and asthenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"     \"Assessment and management of depression in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Comprehensive reviews of assessment tools and scales are available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. For clinical purposes, the Brief Pain Inventory (BPI and its short-form version",
"    <a class=\"external\" href=\"file://www.npcrc.org/usr_doc/adhoc/painsymptom/briefpain_short.pdf\">",
"     (BPI-SF)",
"    </a>",
"    ), the",
"    <a class=\"external\" href=\"file://www.palliative.org/NewPC/_pdfs/tools/ESAS-r.pdf\">",
"     revised Edmonton Symptom Assessment System (ESAS-r)",
"    </a>",
"    , or Memorial Symptom Assessment Scale (MSAS) (",
"    <a class=\"graphic graphic_figure graphicRef60205 \" href=\"UTD.htm?23/13/23762\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/34\">",
"     34",
"    </a>",
"    ]&nbsp;are all reasonable tools. A consistent utilization of a 4-point grading scale (0 = none, 3 = severe) of the subjective burden of individual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/35\">",
"     35",
"    </a>",
"    ]&nbsp;or distress thermometer is also an accepted strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Assessment and rating instruments for symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician must understand the patient's priorities and goals for symptom relief. A convenient way to elicit individual expectations is to ask the patient to rate their degree of distress on a scale [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/37\">",
"     37",
"    </a>",
"    ]&nbsp;and determine",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    desired level of relief; this may be expressed either numerically, nominally or in the acceptable level of interference in activities of daily functioning. Independent of rating intensity of symptoms, asking about, and further assessing the patient's 'most troublesome' symptom uncovers additional, unexpected burdens in almost one-third of palliative care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, this may not all be possible during the first encounter. A comprehensive palliative assessment frequently extends over multiple encounters due to the complexity of the clinical content and time required to develop necessary rapport. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672064\">",
"    <span class=\"h2\">",
"     Psychological, psychiatric and cognitive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key psychological symptoms requiring assessment are depression (as distinct from adjustment and grief), anxiety, delirium, and coping with illness. Clinicians should screen for the multiple factors that increase the prevalence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of psychological distress (rapidly advancing disease, medications such as interferon or glucocorticoids, metabolic abnormalities, uncontrolled pain, impaired cognition, financial distress) and address them, if possible. Psychological distress frequently lessens with adequate pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672071\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of mood disorders and conditions seen in palliative care patients includes normal grief reaction (including anticipatory grief), pathologic grief, adjustment disorder with depressed features, and minor as well as major depression. A summary of some of the contrasting characteristics of normal grief versus depression in terminally-ill patients is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef53062 \" href=\"UTD.htm?35/46/36587\">",
"     table 7",
"    </a>",
"    ), and this subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment and management of depression in palliative care\", section on 'Assessment and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link&amp;anchor=H2#H2\">",
"     \"Grief and bereavement\", section on 'Normal bereavement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link&amp;anchor=H6#H6\">",
"     \"Grief and bereavement\", section on 'Abnormal bereavement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mood disorders are frequent in patients with a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness. As an example, in a meta-analysis, there was a 25 percent combined prevalence of all types of depression, and 38 percent prevalence of mood disorders among palliative care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/40\">",
"     40",
"    </a>",
"    ]. The impact of mood disorders in palliative care is underscored by one study which found that mortality rates in cancer patients are up to 25 percent higher in those who experience depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of screening tools for depression are available. In general, abbreviated screening instruments (",
"    <a class=\"graphic graphic_table graphicRef61549 \" href=\"UTD.htm?28/53/29531\">",
"     table 8",
"    </a>",
"    ) appear to be as effective as longer instruments to screen for depression. Another simple screening strategy for mood disorder and psychosocial distress utilizes the Distress and Impact Thermometer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/42\">",
"     42",
"    </a>",
"    ]&nbsp;or other ultra-short methods [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/43\">",
"     43",
"    </a>",
"    ]. Importantly, these brief tools are designed for screening patients who may subsequently need a full diagnostic evaluation. The subject of screening for depression in palliative care patients is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H19#H19\">",
"     \"Assessment and management of depression in palliative care\", section on 'Simple screening instruments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H2853694#H2853694\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Sadness, grief, and depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672078\">",
"    <span class=\"h3\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is common in patients with an advanced serious or life-threatening illness. Anxiety may also be the result of a preexisting anxiety disorder, substance abuse, delirium, or under-treated symptoms, most commonly pain. Significant factors that may exacerbate anxiety include concerns about future symptom control, the course of the disease, and other components of total pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H2853905#H2853905\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Anxiety'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single aggregate question (&ldquo;Have you felt anxious, nervous, uneasy, tense, or frightened in the recent days&rdquo;) can be utilized to screen for anxiety. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H2853905#H2853905\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Anxiety'",
"    </a>",
"    .) Two formal instruments are available to assess anxiety:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Patient Health Questionnaire (PHQ) is a series of diagnostic tools for mental health disorders used by health care professionals that is quick and easy for patients to complete; the main PHQ tool includes questions about anxiety, and there is a separate instrument to assess mood (the PHQ-9) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A seven-item anxiety scale, the GAD (Generalized Anxiety Disorder)-7 can be used to quantify anxiety (",
"      <a class=\"graphic graphic_table graphicRef77755 \" href=\"UTD.htm?31/30/32236\">",
"       table 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672085\">",
"    <span class=\"h3\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In advanced serious or life-threatening illness, delirium is common, but it is reversible in up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/46\">",
"     46",
"    </a>",
"    ], underscoring the importance of early recognition and aggressive evaluation and management. A mnemonic FACT recalls the diagnostic criteria of delirium (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of delirium and confusional states\", section on 'Recognizing the disorder'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluctuating cognitive deficit(s) with acute onset",
"     </li>",
"     <li>",
"      Attention deficits, and either",
"     </li>",
"     <li>",
"      Consciousness level disturbance, or",
"     </li>",
"     <li>",
"      Thought disorganization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several tools are available to screen for delirium including the Confusion Assessment Method (CAM), the bedside confusion scale (ability to recite the months backwards and assessment of consciousness state), use of serial-sevens and spelling a word such as &ldquo;farm&rdquo; or &ldquo;world&rdquo; backward. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H2861007#H2861007\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Delirium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672092\">",
"    <span class=\"h3\">",
"     Coping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coping refers to a patient&rsquo;s adjustment and psychological rebalancing to manage the demands of a life-threatening illness. Adaptive processing may utilize a variety of factors and styles, including humor, anticipation (planning, active management), disclosure and sharing with",
"    <span class=\"nowrap\">",
"     others/seeking",
"    </span>",
"    support, positive reframing, sublimation, and suppression (distraction, compartmentalization) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/47\">",
"     47",
"    </a>",
"    ]. In contrast, maladaptive coping strategies may include denial, venting, disengagement and avoidance, self-blame, anxious preoccupation, and substance use, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/48\">",
"     48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Ideally, adaptive coping results in altered, but nevertheless satisfactory and sometimes enhanced functional, emotional, and spiritual well-being in spite of progressive illness. In contrast, maladaptive coping is associated with increased stress and higher burden of illness. In one study, for example, low scores on a basic component of effective coping, prognostic acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/49\">",
"     49",
"    </a>",
"    ], were associated with increased hopelessness, depression, and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/49\">",
"     49",
"    </a>",
"    ]. Importantly, a patient&rsquo;s personality and native cultural paradigms can determine whether the emotion regulation style is adaptive or maladaptive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A binomial categorization of coping styles into the so-called &ldquo;monitoring&rdquo; (attending to) and &ldquo;blunting&rdquo; (avoiding) styles has been sometimes invoked [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/50\">",
"       50",
"      </a>",
"      ], but there is little evidence that this characterization aids in clinical practice, except possibly in tailoring the amount of information to be shared with the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/51\">",
"       51",
"      </a>",
"      ]. In one report, patients with a monitoring style of coping tended to do better when given more information, while those with a blunting style did better with less information [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of breast cancer patients, expressive disclosure was associated with increased distress in those with baseline avoidance-oriented coping [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acknowledgment and experience of strong emotions associated with a life-threatening illness can contribute to adjustment as long as those emotions are appraised and integrated. A successful integration usually involves one of the adaptive coping processes (listed above). For instance, adaptive coping may involve expressive disclosure to",
"    <span class=\"nowrap\">",
"     friends/family,",
"    </span>",
"    followed by reframing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seeking support. The clinician&rsquo;s role is to evaluate and facilitate the best adjustment styles; the presence of adaptive coping should be explicitly noted, and commented on by the clinician to reinforce positive coping patterns. In addition to the assessment and reinforcement function, such inquiry communicates concern and compassion to the patient and his or her family.",
"   </p>",
"   <p>",
"    Patients should be asked directly about their coping with the illness; general screening questions such as, &ldquo;",
"    <em>",
"     Have you had anything like this illness happen before? How have you coped in the past?&rdquo;",
"    </em>",
"    or: &ldquo;",
"    <em>",
"     How are you getting through (coping with) this illness?&rdquo;",
"    </em>",
"    can be utilized. When the open ended interview does not yield diagnostic information, focused questions: &ldquo;",
"    <em>",
"     Does",
"     <span class=\"nowrap\">",
"      humor/planning/seeking",
"     </span>",
"     help and support, etc, help you cope with your illness?&rdquo;",
"    </em>",
"    may aid in defining the patient adaptive style.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14431744\">",
"    <span class=\"h3\">",
"     Psychologic issues specific to caregivers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological distress and coping among family and caregivers must be assessed as well. At least one study confirms increased mortality in caregivers who experience mental or emotional strain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/53\">",
"     53",
"    </a>",
"    ], while others report an increased risk of post-traumatic stress and prolonged grief disorders in family caregivers of patients with cancer who died in a hospital or an intensive care unit versus at home [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening for psychological morbidities among caregivers can utilize the same items and approaches that are used for patient assessment. (See",
"    <a class=\"local\" href=\"#H11672071\">",
"     'Depression'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11672078\">",
"     'Anxiety'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Unique family distress assessment items related to socioeconomic needs are listed below. (See",
"    <a class=\"local\" href=\"#H11672106\">",
"     'Social and economic needs of patients and caregivers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672099\">",
"    <span class=\"h2\">",
"     Illness understanding and care preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;This domain focuses on assessment of the patient&rsquo;s degree of informed participation in decision making and planning regarding their illness. A benchmark of good palliative care is how well the administered therapies conform to the patient&rsquo;s informed preferences. Ethical and legal standards for discerning health care preferences are derived from the tradition of individual liberty, and the corresponding principles of patient autonomy and informed consent. These subjects are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=see_link\">",
"     \"Legal aspects of end of life care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H12#H12\">",
"     \"Ethical issues near the end of life\", section on 'Withholding and withdrawing care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to selection, appointment, limitations, and duties of surrogate decision makers are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H4#H4\">",
"     \"Ethical issues near the end of life\", section on 'Surrogate decision makers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Informed care preferences should be formulated in a genuinely shared effort of the patient and the physician. First, a comprehensive review of medical records, the history and the physical examination provides the palliative clinician with an accurate understanding of the patient&rsquo;s illness and where it falls in the natural history of the condition. Prognosis and clinical trajectory, including complications, functional decline, and corresponding needs must be anticipated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19735?source=see_link\">",
"     \"Communication of prognosis in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link\">",
"     \"Survival estimates in advanced terminal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thereafter, the patient&rsquo;s and family&rsquo;s understanding of the illness and preferences for extent of disclosure must be assessed. A dialog, aimed to reconcile the clinical facts ascertained by the physician and subjective hopes and expectations of the patient should follow. In circumstances of gross misunderstanding of the prognosis, or dissonance between expectations and feasible outcomes, the physician should, in a tactful manner that is respectful of the patient&rsquo;s cultural norms and individual preferences for disclosure, counsel and educate the patient and family. &nbsp;",
"   </p>",
"   <p>",
"    Patients&rsquo; values and preferences as well as their understanding of the illness trajectory, prognosis, and treatment can be assessed with a combination of any of the following questions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;What is your understanding of the nature of your illness and what to expect of it?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you feel",
"      <span class=\"nowrap\">",
"       heard/listened",
"      </span>",
"      to? Do you feel you have control of your care?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;What are your most important hopes?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A related assessment process, known as advance care planning, which is undertaken prospectively and sometimes ahead of serious illness, may result in preparation of documents such as an advance directive, living will",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    appointment of a health care proxy. Helpful exploratory questions that can be used in the advanced care planning process are outlined in a table (",
"    <a class=\"graphic graphic_table graphicRef87344 \" href=\"UTD.htm?14/55/15227\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structured approaches to discerning and documenting patients&rsquo; preferences and advanced care planning exist. Some, such as the physician orders for life sustaining treatment (",
"    <a class=\"external\" href=\"file://www.polst.org\">",
"     POLST",
"    </a>",
"    ), are intended for use by physicians and physician extenders, while others may be disease specific or involve periodic assessments by non-physician facilitators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the degree of instability of prospective care choices over time, as well as limited applicability or access to the advance care planning documents at the time of a crisis, an &lsquo;in-the-moment&rsquo; approach to discerning care preferences may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/59\">",
"     59",
"    </a>",
"    ]. The subject of advance directives is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"     \"Ethical issues near the end of life\", section on 'Advance care planning'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14432240\">",
"    <span class=\"h3\">",
"     Ramifications of accurate illness understanding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, many physicians assumed that open and honest communication about advanced illness would risk exacerbating a patient&rsquo;s psychological distress by &ldquo;denying hope&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/61\">",
"     61",
"    </a>",
"    ]. Observational research has suggested the opposite; not only do patients with advanced cancer prefer tactful and timely disclosure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], but non-disclosure is associated with a lower quality of life (QOL), greater utilization of non-beneficial intensive care, and higher rates of major depression in survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Indeed, most patients with a chronic, progressive illness state a preference for disclosure, with information about treatment options, benefits, and burdens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, even with disclosure, major challenges to making genuinely informed health decisions in palliative care remain. As an example, physicians caring for patients with advanced cancer tend to overestimate prognosis. Integration of physician estimates with predictors such as performance status and clinical signs of symptoms (eg, in the Palliative Prognostic Index, (",
"    <a class=\"graphic graphic_table graphicRef71424 \" href=\"UTD.htm?7/61/8156\">",
"     table 11",
"    </a>",
"    )) may improve survival predictions. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link\">",
"     \"Survival estimates in advanced terminal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link&amp;anchor=H2#H2\">",
"     \"Survival estimates in advanced terminal cancer\", section on 'Accuracy of survival estimates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, patients with advanced life-threatening illness also frequently overestimate their prognosis, and this can affect treatment choices. As an example, among cancer patients, the more optimistic the expectation, the greater the likelihood of selecting aggressive treatments which do not improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/67\">",
"     67",
"    </a>",
"    ]. Indeed, one study demonstrated that a majority of patients with incurable stage IV colon and lung cancer mistakenly believed that their malignancies were curable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/22\">",
"     22",
"    </a>",
"    ]. Similar overestimates of survival have been reported among patients with respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/68\">",
"     68",
"    </a>",
"    ], heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/69\">",
"     69",
"    </a>",
"    ]&nbsp;and among the parents of children with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, other patients may hold excessively pessimistic views about their own adaptability and future QOL, thereby risking premature limitation of care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/71\">",
"     71",
"    </a>",
"    ]. These findings underscore the need to assess and correct for cognitive and emotional biases of patients and their families which, if not elucidated, could compromise the patient&rsquo;s autonomous self-determination in palliative care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672106\">",
"    <span class=\"h2\">",
"     Social and economic needs of patients and caregivers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced illness and their caregivers frequently experience profound financial and social strain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/72\">",
"     72",
"    </a>",
"    ]. Family and friends provide most of the assistance to terminally ill patients, for a mean of 43 hours per week [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/73\">",
"     73",
"    </a>",
"    ]. Almost one-third of the families of seriously ill adults report loss of all or most of their savings due to the illness and need for caregiving [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/74\">",
"     74",
"    </a>",
"    ]. Furthermore, economic burden may profoundly impact health care decisions. In one study, economic hardship on the family was associated with a preference for comfort care over life-extending care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/75\">",
"     75",
"    </a>",
"    ]; in another, substantial caregiving needs were associated with terminally ill patients being more likely to consider euthanasia or physician assisted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial screening for socioeconomic distress can be performed utilizing the following questions of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;What kind of help do you need at home? Cooking and shopping? Help with your medications? Getting around the house? Transportation to appointments? Additional equipment or supplies?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Who can help you at home? Is anyone around all the time? Are you getting help from home health aides or visiting nurses?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Has your illness created a financial strain on you and your family?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you worry that you may become a burden to your family?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After determining what help is provided by family members, their needs and distress can be assessed with a question such as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;How much of a mental or emotional strain is it on you to either provide the help directly, or to arrange for help to be provided [for this activity]?\" (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link&amp;anchor=H17#H17\">",
"       \"Psychosocial issues at the end of life\", section on 'Economic circumstances and disparities in medical care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672113\">",
"    <span class=\"h2\">",
"     Religious, spiritual, and existential (transcendent) issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;An impending health crisis occasions a patient&rsquo;s examination of personal values, relationships, and the meaning of life and death. Life-threatening illness evokes questions like &ldquo;Why me?&rdquo;, and &ldquo;Is there anything that transcends death?&rdquo; Therefore, in addition to assessing spirituality and religious beliefs, the tasks of palliative evaluation, as enumerated in the",
"    <a class=\"external\" href=\"file://www.nationalconsensusproject.org/Guideline.pdf\">",
"     Clinical Practice Guidelines for Quality Palliative Care",
"    </a>",
"    of the National Consensus Project for Quality Palliative Care (NCP) include an assessment of hopes and fears, meaning, purpose, beliefs about afterlife, guilt, forgiveness, and life review and completion.",
"   </p>",
"   <p>",
"    Many patients hold denominational beliefs that can profoundly impact medical care, including transfusions, mechanical ventilation, hydration and nutrition, the role of miracles, or physician assisted death. For instance, a high level of relying on religious faith to cope with cancer has been associated with utilizing more ICU care near death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/77\">",
"     77",
"    </a>",
"    ]. It is imperative that a comprehensive palliative assessment probe such beliefs and guide&nbsp;shared physician-patient decision-making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link&amp;anchor=H14#H14\">",
"     \"Religion, spirituality, and end of life care\", section on 'Practices of major world religions'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Along with the prescriptive impact of religious tenets, most cancer patients endorse the importance of religion in coping with their illness. Many, however, report insufficient levels of spiritual support from their communities and the medical system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/78\">",
"     78",
"    </a>",
"    ] in the last weeks of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link&amp;anchor=H13#H13\">",
"     \"Psychosocial issues at the end of life\", section on 'Maintaining hope'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link&amp;anchor=H98972178#H98972178\">",
"     \"Psychosocial issues at the end of life\", section on 'Spiritual beliefs and religious community'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, screening for distress or unmet needs as well as a spiritual history and&nbsp;spiritual assessment are recommended in guidelines from the Consensus Conference on Quality of Spiritual Care as a Dimension of Palliative Care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/79\">",
"     79",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Screening may utilize questions such as, &ldquo;Are spirituality or religion important in your life?&rdquo;; &ldquo;What brings purpose to your life?&rdquo; or &ldquo;Are you at peace?&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/80\">",
"     80",
"    </a>",
"    ]. Several formal tools (FICA, SPIRIT, HOPE) are available for obtaining a spiritual history (",
"    <a class=\"graphic graphic_table graphicRef63804 \" href=\"UTD.htm?39/1/39964\">",
"     table 12",
"    </a>",
"    ), a task assigned by the Consensus Conference to the principal physician or a counseling social worker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/79\">",
"     79",
"    </a>",
"    ]. These instruments standardize assessment of common spiritual themes, identified through qualitative studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spiritual assessment is best completed by a trained",
"    <span class=\"nowrap\">",
"     chaplain/counselor",
"    </span>",
"    and accomplished in an open dialogue and empathic listening. It may include exploratory and interpretive questions such as:",
"    <em>",
"     Where do you find the strength to face your illness? Are you suffering? Are you frightened by thoughts of dying? Do you ever wonder whether God has abandoned you?",
"    </em>",
"   </p>",
"   <p>",
"    Clinicians should be particularly sensitive to comments that might indicate spiritual need or distress. Often, patients express spiritual need with comments that hint at an underlying fear, despair, guilt, desire for a hastened death, or hopelessness. For instance, the guilt and self-blame of a patient with a distant history of alcoholism and later facing a hepatocellular carcinoma may lead to a fatalistic and harmful refusal of effective therapies. When utilizing a focused interview, the palliative clinician should be able to detect such problems (see interview question in spiritual assessment, above), offer support and clarifications, and refer for proper counseling.",
"   </p>",
"   <p>",
"    To assess the transcendent needs of non-religious or non-spiritual patients requires&nbsp;a particular sensitivity. Concerns of atheist patients are frequently of a moral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    humanistic nature and can be evaluated with careful dialog, as long as it maintains respect for rationalism, non-belief and withholds prayer or references to God. An interview question such as,",
"    <em>",
"     &ldquo;This sort of illness often raises significant questions&hellip; How are you dealing with this?&rdquo;",
"    </em>",
"    communicates compassion and concern while facilitating assessment.",
"    <em>",
"    </em>",
"   </p>",
"   <p>",
"    Another aspect of transcendent domain assessment pertains to life review. Common themes include completion of life affairs, contribution to others, and legacy; concern for these tasks emerges with the diagnosis of a life-limiting illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/82\">",
"     82",
"    </a>",
"    ]. Assessment and facilitation of life review can be deployed as a sequence of assessment questions and facilitated patient&rsquo;s answers, a process akin to Dignity Therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/83\">",
"     83",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H25#H25\">",
"     \"Assessment and management of depression in palliative care\", section on 'Existential psychotherapy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;How would you want to be remembered?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;What do you feel most proud of (in your life)?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you feel prepared for what is still ahead of you? What would be left unfinished if you were to die today? What do you still want to accomplish in your life?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Have you been able to share important lessons, thoughts and things with others?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Are there particular things that you feel still need to be said to your loved ones? Is there anyone to whom you wish to offer",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      ask for) forgiveness? Are there things or times you regret?&rdquo; Physicians must recognize, however, that patients may not wish to speak to their doctors about these matters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672120\">",
"    <span class=\"h2\">",
"     Care coordination and continuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care transitions risk fragmentation and duplication of care while increasing the potential for medical error [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/84\">",
"     84",
"    </a>",
"    ]. Among elderly patients with cognitive problems, burdensome transitions (defined as those occurring in the last three days of life, involving transfer between multiple care facilities, or including multiple hospitalizations in the last 90 days of life) are associated with poor outcomes, such as increased ICU care in the last month of life and increased complications, such as pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/85\">",
"     85",
"    </a>",
"    ]. Similar shortcomings, attributable to discontinuity of care, have been identified in patients with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive palliative care assessment should discern what transitions are avoidable and how to better coordinate care to avoid trauma, confusion, and unwanted treatment. This task requires facilitation of advance care and discharge planning. One qualitative study suggested the three concerns that need assessment prior to hospital discharge or other transitions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/87\">",
"     87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discernment of patient and family understanding of the condition and prognosis and tactful clarification if gaps are identified (see",
"      <a class=\"local\" href=\"#H11672099\">",
"       'Illness understanding and care preferences'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Reassessment of ongoing symptom burden with individual therapeutic plan(s) for relief (see",
"      <a class=\"local\" href=\"#H9239028\">",
"       'Physical symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11672064\">",
"       'Psychological, psychiatric and cognitive symptoms'",
"      </a>",
"      above) &nbsp;",
"     </li>",
"     <li>",
"      Identification of a communication chain (who to call with what kind of concerns) and follow-up plan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Care coordination should involve physicians as well as non-physician members of the interdisciplinary team, such as advanced practice nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/88\">",
"     88",
"    </a>",
"    ], transition coaches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/89\">",
"     89",
"    </a>",
"    ], or case managers and social workers. Resources are available to facilitate care transitions from the",
"    <a class=\"external\" href=\"file://www.caretransitions.org/four_pillars.asp\">",
"     Care Transitions Program",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672127\">",
"    <span class=\"h1\">",
"     DOCUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of the comprehensive palliative consult includes summaries of all six domains described above, ideally, structured and organized according to the subjective order of burden of each of the symptoms. The 10 principles of effective consultation, as originally published in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/92\">",
"     92",
"    </a>",
"    ], are directly applicable to the conduct and documentation of palliative consultations (",
"    <a class=\"graphic graphic_table graphicRef87191 \" href=\"UTD.htm?18/63/19451\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672134\">",
"    <span class=\"h1\">",
"     GUIDELINES AND TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several guidelines pertaining to overall palliative patient assessment are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672141\">",
"    <span class=\"h2\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;General palliative care assessment guidelines for cancer patients, available from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN),",
"    </a>",
"    suggest inclusion of",
"    <span class=\"nowrap\">",
"     benefits/risks",
"    </span>",
"    of anticancer therapy, physical symptoms, psychosocial distress, personal goals and expectations, education and informational needs, and cultural factors affecting care. They also provide criteria for early consultation with a palliative care specialist (",
"    <a class=\"graphic graphic_table graphicRef87162 \" href=\"UTD.htm?24/46/25324\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11672759\">",
"     'Identifying patients who need a palliative care assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672148\">",
"    <span class=\"h2\">",
"     National Consensus Project",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for palliative care assessment, which are applicable to disease other than cancer, are available from the National Consensus Project for Quality Palliative Care (",
"    <a class=\"external\" href=\"file://www.nationalconsensusproject.org/Guideline.pdf\">",
"     the Clinical Practice Guidelines for Quality Palliative Care",
"    </a>",
"    ). The assessment domains include the structure and processes of care, and physical,",
"    <span class=\"nowrap\">",
"     psychological/psychiatric,",
"    </span>",
"    social,",
"    <span class=\"nowrap\">",
"     spiritual/religious/existential,",
"    </span>",
"    and cultural aspects of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672155\">",
"    <span class=\"h2\">",
"     Use of tools to guide assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several structured assessment methods have been proposed, including electronic collection of assessment data and methods to notify the clinician of patient distress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/32,94,95\">",
"     32,94,95",
"    </a>",
"    ]. Specific assessment tools for physical symptoms in palliative care patients are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Assessment and rating instruments for symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controlled trials of care guided by at least one validated assessment tool, the NEST13+ (Needs At the End-of-Life Screening Tool-13) were able to detect unaddressed needs in cancer care settings, although detection did not carry through to demonstrated improvements in clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/23,94\">",
"     23,94",
"    </a>",
"    ]. Each domain of the NEST13+, in turn, has inventory subcategories (analogous to the traditional review of systems) to help elaborate the patient's distress and needs.",
"   </p>",
"   <p>",
"    Other examples of comprehensive assessment and documentation tools include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient-Reported Outcomes Measurement Information System (PROMIS,",
"      <a class=\"external\" href=\"file://www.nihpromis.org/\">",
"       www.nihpromis.org",
"      </a>",
"      , [",
"      <a class=\"abstract\" href=\"UTD.htm?27/52/28490/abstract/96\">",
"       96",
"      </a>",
"      ]), as developed by the US National Institutes of Health (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of health-related quality of life\", section on 'Combined instruments for patient-reported outcomes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&amp;pageId=86426\">",
"       Interactive Symptom Assessment and Collection",
"      </a>",
"      (ISAAC), developed and hosted by Cancer Care Ontario",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.palliative.org/NewPC/_pdfs/tools/ESAS-r.pdf\">",
"       The revised Edmonton Symptom Assessment Scale (ESAS-r)",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/pdf/distress.pdf\">",
"       NCCN Distress Thermometer",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11672162\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with an advanced, serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life-threatening illness, palliative care is an interdisciplinary collaboration that focuses on patient-defined goals of care and relief of the patient&rsquo;s and family's distress. While palliative care used to be seen as care that was provided for people who were not receiving any active treatment for cancer and were in fact dying of their disease, the principles of palliative care are equally applicable to early stage, potentially curable disease. Palliative care can and should be provided alongside disease modifying treatment. (See",
"      <a class=\"local\" href=\"#H11672006\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perceptions of discomfort and burden of illness among palliative care patients are highly individualized. \"Total pain\" describes the complex etiology of pain, including its physical, emotional, social (including economic), and spiritual components. Besides pain, personal suffering can also be influenced by an individual&rsquo;s body image, their sense of the past",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      future, the meaning of their illness, and their desires, relationships, values, or spiritual beliefs. (See",
"      <a class=\"local\" href=\"#H11672013\">",
"       'Sources and clinical manifestations of suffering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consensus-based guidelines are available to identify patients in need of general palliative assessment at the time of hospital admission (",
"      <a class=\"graphic graphic_table graphicRef76969 \" href=\"UTD.htm?30/62/31724\">",
"       table 1",
"      </a>",
"      ). Analogous, detailed criteria for palliative care assessment and specialist referral are available for cancer patients, including those being cared for in the outpatient setting, from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef87162 \" href=\"UTD.htm?24/46/25324\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11672759\">",
"       'Identifying patients who need a palliative care assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the scope of the palliative care needs that arise in patients with an advanced serious",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      life-threatening illness, optimal care requires a unique evaluative approach. The domains of the comprehensive palliative assessment include physical symptoms;",
"      <span class=\"nowrap\">",
"       psychological/psychiatric",
"      </span>",
"      and cognitive symptoms; illness understanding and care preferences; social and economic needs; existential, religious, and spiritual issues; and care coordination and continuity. (See",
"      <a class=\"local\" href=\"#H11672056\">",
"       'Domains of palliative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systematic comprehensive approaches are preferred. However, a comprehensive palliative assessment is rarely completed in one session, frequently extending over multiple encounters and involving non-physician interdisciplinary team members. (See",
"      <a class=\"local\" href=\"#H734093\">",
"       'Unique aspects of palliative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Documentation of the comprehensive palliative consult includes summaries of all six domains described above. (See",
"      <a class=\"local\" href=\"#H11672127\">",
"       'Documentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General palliative care assessment guidelines are available from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      and the National Consensus Project (",
"      <a class=\"external\" href=\"file://www.nationalconsensusproject.org/Guideline.pdf\">",
"       the Clinical Practice Guidelines for Quality Palliative Care",
"      </a>",
"      ). In addition, several structured assessment tools are available to guide patient assessment (see",
"      <a class=\"local\" href=\"#H11672134\">",
"       'Guidelines and tools'",
"      </a>",
"      above). The subject of symptom assessment in palliative care patients is addressed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"       \"Approach to symptom assessment in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/1\">",
"      Sep&uacute;lveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. J Pain Symptom Manage 2002; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     Saunders C. The depths and the possible heights. Medical News July 10, 1964. p.16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/3\">",
"      Wilson KG, Chochinov HM, McPherson CJ, et al. Suffering with advanced cancer. J Clin Oncol 2007; 25:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/4\">",
"      Cassell EJ. Recognizing suffering. Hastings Cent Rep 1991; 21:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/5\">",
"      Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/6\">",
"      Munday D, Petrova M, Dale J. Exploring preferences for place of death with terminally ill patients: qualitative study of experiences of general practitioners and community nurses in England. BMJ 2009; 339:b2391.",
"     </a>",
"    </li>",
"    <li>",
"     Hearing before the Subcommittee on Health of the US House of Representatives Committee on Ways and Means: Coverage of hospice care under the Medicare program, 97th Cong, 2nd Sess, March 25, 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/8\">",
"      Snyder CF, Dy SM, Hendricks DE, et al. Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer 2007; 15:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/9\">",
"      Tishelman C, L&ouml;vgren M, Broberger E, et al. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis. J Clin Oncol 2010; 28:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/10\">",
"      Silvestri GA, Knittig S, Zoller JS, Nietert PJ. Importance of faith on medical decisions regarding cancer care. J Clin Oncol 2003; 21:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/11\">",
"      Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet 2001; 357:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/12\">",
"      Barazzetti G, Borreani C, Miccinesi G, Toscani F. What \"best practice\" could be in Palliative Care: an analysis of statements on practice and ethics expressed by the main Health Organizations. BMC Palliat Care 2010; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/13\">",
"      Granek L, Tozer R, Mazzotta P, et al. Nature and impact of grief over patient loss on oncologists' personal and professional lives. Arch Intern Med 2012; 172:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/14\">",
"      Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/15\">",
"      Barclay S, Momen N, Case-Upton S, et al. End-of-life care conversations with heart failure patients: a systematic literature review and narrative synthesis. Br J Gen Pract 2011; 61:e49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/16\">",
"      Janssen DJ, Spruit MA, Uszko-Lencer NH, et al. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011; 14:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/17\">",
"      Dow LA, Matsuyama RK, Ramakrishnan V, et al. Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol 2010; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/18\">",
"      Haidet P, Hamel MB, Davis RB, et al. Outcomes, preferences for resuscitation, and physician-patient communication among patients with metastatic colorectal cancer. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Am J Med 1998; 105:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/19\">",
"      Str&ouml;mgren AS, Groenvold M, Pedersen L, et al. Does the medical record cover the symptoms experienced by cancer patients receiving palliative care? A comparison of the record and patient self-rating. J Pain Symptom Manage 2001; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/20\">",
"      DesHarnais S, Carter RE, Hennessy W, et al. Lack of concordance between physician and patient: reports on end-of-life care discussions. J Palliat Med 2007; 10:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/21\">",
"      Mack JW, Weeks JC, Wright AA, et al. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 2010; 28:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/22\">",
"      Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/23\">",
"      Scandrett KG, Reitschuler-Cross EB, Nelson L, et al. Feasibility and effectiveness of the NEST13+ as a screening tool for advanced illness care needs. J Palliat Med 2010; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/24\">",
"      Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med 2008; 148:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/25\">",
"      Cassell EJ. Diagnosing suffering: a perspective. Ann Intern Med 1999; 131:531.",
"     </a>",
"    </li>",
"    <li>",
"     Worcester A. The Care of the Aged, the Dying and the Dead, Arno Press, New York 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/27\">",
"      Pollak KI, Arnold RM, Jeffreys AS, et al. Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 2007; 25:5748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/28\">",
"      Back AL, Arnold RM, Quill TE. Hope for the best, and prepare for the worst. Ann Intern Med 2003; 138:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/29\">",
"      Lautrette A, Darmon M, Megarbane B, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med 2007; 356:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/30\">",
"      Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting: a consensus report from the Center to Advance Palliative Care. J Palliat Med 2011; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/31\">",
"      Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     Brown University. Toolkit of instruments to measure end-of-life care. www.chcr.brown.edu/pcoc/toolkit.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/33\">",
"      Richardson A, Medina J, Brown V, Sitzia J. Patients' needs assessment in cancer care: a review of assessment tools. Support Care Cancer 2007; 15:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/34\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/35\">",
"      Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001; 93:247.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/37\">",
"      Str&ouml;mgren AS, Sjogren P, Goldschmidt D, et al. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 2006; 31:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/38\">",
"      Hoekstra J, Vernooij-Dassen MJ, de Vos R, Bindels PJ. The added value of assessing the 'most troublesome' symptom among patients with cancer in the palliative phase. Patient Educ Couns 2007; 65:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/39\">",
"      Mystakidou K, Tsilika E, Parpa E, et al. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nurs 2006; 29:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/40\">",
"      Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/41\">",
"      Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115:5349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/42\">",
"      Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage 2005; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/43\">",
"      Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 2007; 25:4670.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.phqscreeners.com/ (Accessed on February 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/45\">",
"      Spitzer RL, Kroenke K, Williams JB, L&ouml;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/46\">",
"      Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/47\">",
"      Andrews G, Singh M, Bond M. The Defense Style Questionnaire. J Nerv Ment Dis 1993; 181:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/48\">",
"      Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med 1997; 4:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/49\">",
"      Thompson GN, Chochinov HM, Wilson KG, et al. Prognostic acceptance and the well-being of patients receiving palliative care for cancer. J Clin Oncol 2009; 27:5757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/50\">",
"      Miller SM, Brody DS, Summerton J. Styles of coping with threat: implications for health. J Pers Soc Psychol 1988; 54:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/51\">",
"      Miller SM. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Cancer 1995; 76:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/52\">",
"      Stanton AL, Danoff-Burg S, Sworowski LA, et al. Randomized, controlled trial of written emotional expression and benefit finding in breast cancer patients. J Clin Oncol 2002; 20:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/53\">",
"      Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/54\">",
"      Wright AA, Keating NL, Balboni TA, et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol 2010; 28:4457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/55\">",
"      Lo B, Quill T, Tulsky J. Discussing palliative care with patients. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 1999; 130:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/56\">",
"      Steinhauser KE, Bosworth HB, Clipp EC, et al. Initial assessment of a new instrument to measure quality of life at the end of life. J Palliat Med 2002; 5:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/57\">",
"      Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA 2001; 286:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/58\">",
"      Tulsky JA. Beyond advance directives: importance of communication skills at the end of life. JAMA 2005; 294:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/59\">",
"      Sudore RL, Fried TR. Redefining the \"planning\" in advance care planning: preparing for end-of-life decision making. Ann Intern Med 2010; 153:256.",
"     </a>",
"    </li>",
"    <li>",
"     Respecting Choices Disease-Specific Advance Care Planning: The Next Steps for Patients with Chronic Progressive Illness. Available at: file://respectingchoices.org/data/gundersen/commercelite/249_42908_DS-ACP%20marketing%20description%20v%207%20FINAL%20typos%20fixed%205-10-10.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/61\">",
"      Gordon EJ, Daugherty CK. 'Hitting you over the head': oncologists' disclosure of prognosis to advanced cancer patients. Bioethics 2003; 17:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/62\">",
"      Apatira L, Boyd EA, Malvar G, et al. Hope, truth, and preparing for death: perspectives of surrogate decision makers. Ann Intern Med 2008; 149:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/63\">",
"      Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manage 2007; 34:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/64\">",
"      Yun YH, Kwon YC, Lee MK, et al. Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. J Clin Oncol 2010; 28:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/65\">",
"      Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/66\">",
"      Fried TR, Bradley EH. What matters to seriously ill older persons making end-of-life treatment decisions?: A qualitative study. J Palliat Med 2003; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/67\">",
"      Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/68\">",
"      Cox CE, Martinu T, Sathy SJ, et al. Expectations and outcomes of prolonged mechanical ventilation. Crit Care Med 2009; 37:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/69\">",
"      Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 2008; 299:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/70\">",
"      Mack JW, Cook EF, Wolfe J, et al. Understanding of prognosis among parents of children with cancer: parental optimism and the parent-physician interaction. J Clin Oncol 2007; 25:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/71\">",
"      Halpern J, Arnold RM. Affective forecasting: an unrecognized challenge in making serious health decisions. J Gen Intern Med 2008; 23:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/72\">",
"      McPherson CJ, Wilson KG, Murray MA. Feeling like a burden to others: a systematic review focusing on the end of life. Palliat Med 2007; 21:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/73\">",
"      Wolff JL, Dy SM, Frick KD, Kasper JD. End-of-life care: findings from a national survey of informal caregivers. Arch Intern Med 2007; 167:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/74\">",
"      Covinsky KE, Goldman L, Cook EF, et al. The impact of serious illness on patients' families. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. JAMA 1994; 272:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/75\">",
"      Covinsky KE, Landefeld CS, Teno J, et al. Is economic hardship on the families of the seriously ill associated with patient and surrogate care preferences? SUPPORT Investigators. Arch Intern Med 1996; 156:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/76\">",
"      Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000; 284:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/77\">",
"      Phelps AC, Maciejewski PK, Nilsson M, et al. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA 2009; 301:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/78\">",
"      Balboni TA, Vanderwerker LC, Block SD, et al. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. J Clin Oncol 2007; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/79\">",
"      Puchalski C, Ferrell B, Virani R, et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009; 12:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/80\">",
"      Steinhauser KE, Voils CI, Clipp EC, et al. \"Are you at peace?\": one item to probe spiritual concerns at the end of life. Arch Intern Med 2006; 166:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/81\">",
"      Alcorn SR, Balboni MJ, Prigerson HG, et al. \"If God wanted me yesterday, I wouldn't be here today\": religious and spiritual themes in patients' experiences of advanced cancer. J Palliat Med 2010; 13:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/82\">",
"      Steinhauser KE, Alexander SC, Byock IR, et al. Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial. J Palliat Med 2008; 11:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/83\">",
"      Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23:5520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/84\">",
"      Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003; 138:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/85\">",
"      Gozalo P, Teno JM, Mitchell SL, et al. End-of-life transitions among nursing home residents with cognitive issues. N Engl J Med 2011; 365:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/86\">",
"      Sharma G, Freeman J, Zhang D, Goodwin JS. Continuity of care and intensive care unit use at the end of life. Arch Intern Med 2009; 169:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/87\">",
"      Benzar E, Hansen L, Kneitel AW, Fromme EK. Discharge planning for palliative care patients: a qualitative analysis. J Palliat Med 2011; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/88\">",
"      Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA 1999; 281:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/89\">",
"      Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. Arch Intern Med 2006; 166:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/90\">",
"      Coleman EA, Smith JD, Frank JC, et al. Preparing patients and caregivers to participate in care delivered across settings: the Care Transitions Intervention. J Am Geriatr Soc 2004; 52:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/91\">",
"      Parry C, Coleman EA, Smith JD, et al. The care transitions intervention: a patient-centered approach to ensuring effective transfers between sites of geriatric care. Home Health Care Serv Q 2003; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/92\">",
"      Goldman L, Lee T, Rudd P. Ten commandments for effective consultations. Arch Intern Med 1983; 143:1753.",
"     </a>",
"    </li>",
"    <li>",
"     Weissman DE. Audio conference: Reaching out to your referring physicians: Part II - Consultation etiquette. New York Center to Advance Palliative Care, September 19, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/94\">",
"      Emanuel LL, Alpert HR, Emanuel EE. Concise screening questions for clinical assessments of terminal care: the needs near the end-of-life care screening tool. J Palliat Med 2001; 4:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/95\">",
"      Abernethy AP, Zafar SY, Uronis H, et al. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manage 2010; 40:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/52/28490/abstract/96\">",
"      Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45:S3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2197 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28490=[""].join("\n");
var outline_f27_52_28490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11672162\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672006\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672013\">",
"      SOURCES AND CLINICAL MANIFESTATIONS OF SUFFERING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672020\">",
"      Diversity of individual experience of suffering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672027\">",
"      Interpersonal sources of suffering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H734218\">",
"      ASSESSMENT OF PALLIATIVE CARE NEEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672034\">",
"      Gaps in general medical assessment&nbsp;in palliative care patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H734093\">",
"      Unique aspects of palliative assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672759\">",
"      Identifying patients who need a palliative care assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672056\">",
"      DOMAINS OF PALLIATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9239028\">",
"      Physical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672064\">",
"      Psychological, psychiatric and cognitive symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11672071\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11672078\">",
"      - Anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11672085\">",
"      - Delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11672092\">",
"      - Coping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14431744\">",
"      - Psychologic issues specific to caregivers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672099\">",
"      Illness understanding and care preferences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14432240\">",
"      - Ramifications of accurate illness understanding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672106\">",
"      Social and economic needs of patients and caregivers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672113\">",
"      Religious, spiritual, and existential (transcendent) issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672120\">",
"      Care coordination and continuity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672127\">",
"      DOCUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672134\">",
"      GUIDELINES AND TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672141\">",
"      National Comprehensive Cancer Network (NCCN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672148\">",
"      National Consensus Project",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11672155\">",
"      Use of tools to guide assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11672162\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2197|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/14/43246\" title=\"algorithm 1\">",
"      Healthcare delivery mods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2197|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/13/23762\" title=\"figure 1\">",
"      Memorial symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2197|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/62/31724\" title=\"table 1\">",
"      Palliative care assessment at admission criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/16/37131\" title=\"table 2\">",
"      Primary palliative care assessment components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/46/25324\" title=\"table 3\">",
"      NCCN criteria for palliative care assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11710\" title=\"table 4\">",
"      Symptom prevalence in palliative care patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/8/33931\" title=\"table 5\">",
"      PAIN RULES mnemonic for palliative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/59/13243\" title=\"table 6\">",
"      MOPQRST mnemonic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/46/36587\" title=\"table 7\">",
"      Characteristic grief depres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/53/29531\" title=\"table 8\">",
"      Abbrev screen depres cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/30/32236\" title=\"table 9\">",
"      GAD-7 anxiety scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/55/15227\" title=\"table 10\">",
"      Exploratory questions for advanced care planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8156\" title=\"table 11\">",
"      Palliative Prognostic Index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/1/39964\" title=\"table 12\">",
"      Instruments spiritual history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/63/19451\" title=\"table 13\">",
"      Principles of consultation etiquette",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30666?source=related_link\">",
"      Assessment and management of dyspnea in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19735?source=related_link\">",
"      Communication of prognosis in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6922?source=related_link\">",
"      Palliative care: Overview of fatigue, weakness, and asthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_52_28491="Myocardial states LV dysfunct";
var content_f27_52_28491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of irreversible and viable myocardial findings in patients with areas of LV dysfunction at rest",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        State of myocardium",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\" rowspan=\"1\">",
"        LV",
"dysfunction at rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irreversibly damaged",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"7\">",
"        Viable and at risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hibernating",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ischemic on \"stress\"",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LV: left ventricular; +: yes; -: no.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28491=[""].join("\n");
var outline_f27_52_28491=null;
var title_f27_52_28492="Zoonoses from dogs A";
var content_f27_52_28492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses dogs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Canine symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Infectious saliva",
"       </td>",
"       <td>",
"        Rabies",
"       </td>",
"       <td>",
"        Acute progressive encephalitis",
"       </td>",
"       <td>",
"        Stages: prodromal, furious, and paralytic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasteurella",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, septic arthritis, osteomyelitis",
"       </td>",
"       <td>",
"        Normal flora of oral cavity",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capnocytophaga",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, sepsis, meningitis",
"       </td>",
"       <td>",
"        Normal flora of oral cavity",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucella",
"       </td>",
"       <td colspan=\"1\">",
"        Fever of unknown origin; varied and nonspecific symptoms",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Fecal",
"       </td>",
"       <td>",
"        Salmonella Cryptosporidium Giardia",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter",
"       </td>",
"       <td>",
"        Abdominal pain and diarrhea",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxocara canis",
"       </td>",
"       <td>",
"        Visceral larva migrans and ocular larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancylostoma caninum",
"       </td>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Most common in ranching areas of the Mediterranean, South America, and Australia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipylidium caninum",
"       </td>",
"       <td>",
"        Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28492=[""].join("\n");
var outline_f27_52_28492=null;
var title_f27_52_28493="Tirofiban unstable angina PRISM";
var content_f27_52_28493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tirofiban reduces mortality in unstable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The PRISM study randomly assigned 3232 patients with unstable angina to therapy with heparin or tirofiban. Tirofiban was associated with a significant reduction in 30-day mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28493=[""].join("\n");
var outline_f27_52_28493=null;
var title_f27_52_28494="Formation of NO by NOS";
var content_f27_52_28494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The enzymatic formation nitric oxide (NO) by nitric oxide synthetase (NOS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 570px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FAD: flavin adenine dinucleotide; FMN: flavin mononucleotide; NADPH: nicotinamide adenine dinucleotide phosphate; NO: nitric oxide; NOS: nitric oxide synthetase; RS-NO: S-nitrosothiols.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Gaston, B, Drazen, JM, Loscalzo, J, Stamler, J, Am J Respir Crit Care Med 1994; 149:538.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28494=[""].join("\n");
var outline_f27_52_28494=null;
var title_f27_52_28495="TB tracheal stenosis CXR";
var content_f27_52_28495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculosis tracheobronchial stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph demonstrates total collapse of right lung, narrowing of the lower trachea, complete occlusion of right mainstem bronchus, and marked hyperexpansion of the left lung, which crosses the midline towards the right hemithorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_52_28495=[""].join("\n");
var outline_f27_52_28495=null;
